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The prostate gland is an organ about the size of a chestnut that consists of
glandular and muscular tissue. It is situated below the neck of the bladder, encircling the
urethra. The prostate produces a thin, milky, alkaline fluid that is secreted into the
urethra at the time of emission of semen, providing an added medium for the life and
motility of sperm. It is probable that prostatic fluid enhances fertility since the fluid
flowing from the testes and seminal vesicles is acidic and sperm are not optimally
mobile unless their medium is relatively alkaline. Normal prostatic glandular tissue is
composed of the principal cell types: luminal epithelial cells, basal epithelial cells, and
stromal smooth muscle cells (Cunha et al. 1996). Basal cells are the presumed
progenitors of luminal cells (Danielpour 1999; Robinson et al. 1998). The latter are the
differentiated, postmitotic secretory cells of the prostate epithelium.
The prostate contributes 15-30 % of the seminal fluid. It reaches its mature size at
puberty. Around age 50, it commonly shrinks and decreases its secretions; an increase
in size after mid-life may be due to inflammation or malignancy, abnormality or disease
of the prostate gland. About halfof all men over 60 have some nonmalignant
enlargement, or benign prostatic hyperplasia (BPH). The gland may eventually
compress the urethra, causing problems urinating. Severe cases can lead to infection,
bladder stones, obstruction, and kidney failure. Prostate cancer, also found mainly in
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older men, can be deadly but usually grows so slowly that most patients die of
something else before the cancer spreads. Since surgery and radiation therapy often lead
to incontinence and impotence, many cases are monitored (through prostate-specific
antigen, or PSA, tests) and treated only if necessary.
Prostate Cancer
Adenocarcinoma of the prostate (PCa), the second highest cause of death by
cancer in US males, is one of the most dreaded diseases in the world (Parker et al. 1997).
At the time ofdiagnosis, prostate cells in nearly 50 % ofpatients have usually spread to
other organs (such as pelvic lymph nodes, pelvic bones) (Parker et al. 1997). Prostate
cancer represents an increasingly large burden on health resources in the Western world.
The prevalence of the disease is rising steadily. In the USA alone there were 83,000
cases in 1985 (Parkin et al. 1993), compared to an estimated 317,000 in 1996 (Parker et
al. 1997). This apparent increase in incidence is thought to be caused in part to
increased detection through screening. The rapid increase in the number of diagnosed
cases appears to result in part from an increase in disease awareness as well as the
widespread screening for clinical markers correlated with PCa (Chiarodo 1991). The
value of treatment with curative intent remains controversial and although the rates of
radical prostatectomy (prostate removal) vary widely in the USA, this does not appear to
have a significant impact on mortality (Lu et al. 1994). PCa is among the most
significant problems in the United States because the disease is now the most common
noncutaneous malignancy diagnosed in American males (Coffey 1993). Survival rates
of patients with prostate cancer may be enhanced if diagnosed at an early stage.
Consequently, reliable tests for early detection are of paramount importance.
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Diagnosis of Prostate Cancer
Targeting the prostate for treatment ofbenign and malignant disease has been the
subject of research for many years. More than 50 years have passed since the first
potential PCa marker was identified in patients with metastatic adenocarcinoma
(Gutman et al. 1936; 1938). The results of these studies revealed that PCa elicited an
elevation ofacid phosphatase activity. Since then, extensive investigative research has
been performed to enhance the reliability of acid phosphatase for diagnosis of early
prostate cancer when the disease is curable (Killian et al. 1990). However, incidence,
morbidity, and mortality, as well as the fact that approximately 50 % ofpatients already
have disseminated disease at the time of diagnosis show how difficult the search has
been for a reliable early tumor marker (Catalona and Scott 1986; Pontes 1983; McNeal
etal. 1988; Stamey 1983).
In 1979, Wang et al. at Roswell Park Memorial Institute identified an effective
imique new marker, one which differed from other serum markers that were in use
(Wang et al. 1979). This marker was named prostate-specific antigen (PSA) because it
was thought to be synthesized exclusively by the prostate. PSA, a glycoprotein (gp) of
33 kilodaltons (kDa) is found in normal, benign, and malignant prostate (Kuriyama and
Wang 1980). PSA, unlike prostatic alkaline phosphatase (PAP), had not been
demonstrated in other tissues or primary malignancies (Killian and Chu 1990). The
expression of antigen is restricted to the cytoplasm of the ductal epithelium and to
secretions in the ductal lumina of the prostate (Papsidero et al. 1981). Since PSA is
organ-site and cell type-specific and a secretory glycoprotein, it can be recovered and
purified from both prostatic tissue and seminal plasma and serum (Wang et al. 1982).
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The use of PSA as a biomarker for PCa has been criticized due to the fact that both
polyclonal (Wang et al. 1979; Nadji and Castro 1981) and monoclonal antibodies
(Frankel et al. 1982; Papsidero et al. 1983) directed against it react with normal and
malignant prostate tissue. This inability to differentiate between a benign and a
malignant process can result in a 20% to 30 % false-positive/false-negative rate
(Schellhammer et al. 1993). Clearly, a biomarker that can differentiate benign from
malignant prostate tumors would have a distinct advantage. PSA as a screening marker
has the potential for detecting localized carcinomas of low biologic potential, thereby
resulting in "over-treatment" with its attendant morbidity (Schellhammer et al. 1993). A
biomarker that can differentiate a clinically important tumor from a clinically
unimportant tumor would have a direct role in determining which patients require
immediate and aggressive therapy and which could be managed expectantly. Therefore,
a biomarker of disease progression, one that can identify the tumor population destined
to metastasize would offer a distinct clinical advantage.
Certain ideal criteria for a tumor marker to be classified as clinically reliable have
been proposed (Javadpour 1984). These criteria include the specificity for cancer,
detectability in biological fluid and tissue extract, a relatively short biologic half-life,
and correlation of a positive marker result with the presence of tumor. The marker
results also should reflect the tumor-bearing status and prognosis ofpatients as well as
correlate with the efficacy of treatment (Killian and Chu 1990).
The production ofmonoclonal antibodies (MAbs) against prostate-specific
antigen has contributed to the development ofmethods for immunological detection of
prostate cancer. For reasons described above, the correlation between elevated levels of
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PSA in serum and PCa is controversial. Therefore, there is a need for an expanded
collection ofPCa-specific MAbs.
A number of other prostate tissue markers have been identified by their potential
usefulness in the diagnosis, prognosis, and treatment ofprostate cancer. In addition to
PSA and PAP, prostate-specific membrane antigen (PSMA), prostatic inhibin peptide
(PIP), and human glandular kallikrein (hK2) have been characterized for PCa and
developed for MAb-based immunoassay (Zundel et al. 1990; Rochon et al. 1994; Garde
et al. 1993; Charlesworth et al. 1997). Expression in PCa cells of several other common
tumor markers such as Tn, sTn, mucins (i.e., MUCl, MUC2, MUC5), herceptin-2
(HER2), carcinoembryonic antigen (CEA), and gangliosides, has been described (Zhang
and Zhang 1998). Despite the progress in characterization of the highly expressed tumor
markers listed above, all of the markers identified thus far are either limited to a few PCa
cell lines, or are also expressed in normal prostatic tissues.
Antibodies that recognize specific cell types promise to be valuable tools both in
research and clinical applications. Cell-specific peptides can be used as drug delivery
vehicles, diagnostic agents, affinity reagents for cell purification, gene therapy delivery
agents, and research tools to probe the nature of a cell's surface (Brown 2000). The
surface of a cell is a landscape ofmacromolecules, specific to the function and state of
the cell. Ligands for specific macromolecules can serve as targeting agents, assuming
that they have specificity for the cell type, and affinities that permit binding under
biological conditions. In the past, efforts in the field of targeted therapies have utilized
MAbs or knovm peptide hormones as homing moieties (Farah et al. 1998).
Prostate Cancer Models
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Several cell lines have been utilized to help gain a better understanding of the
basic mechanisms underlying prostate cancer. For example, the cell lines LNCaP
(Horoszewicz et al. 1983), DU145 (Stone et al. 1978), and PC-3 (Kaighn et al. 1979)
have served as classical tools for in vitro studies of PCa. Although these cell lines have
contributed to the characterization of prostate carcinomas; however, they do not serve as
useful tools in analyzing factors that contribute to the development of this malignancy.
Two human prostate epithelial cell lines, RWPE-1 and RWPE-2, have been
developed to assist in deciphering the factors that lead to PCa. These cell lines were
developed via immortalization of the normal prostatic epithelial cells (to yield the cell
line RWPE-1) with the HPV-18 (human papillomavirus-18) and subsequent induction of
transformation by activated v-Ki-ras (from Kirstine murine sarcoma virus), to form a
tumorigenic cell line RWPE-2 (Bello et al. 1997).
HPV-18, a clinically relevant HPV strain, was used for two reasons. First, HPV-
immortalized cells are more likely to retain growth and differentiation characteristics of
their normal cells oforigin and they are non-tumorigenic (Woodworth et al. 1990;
Yankaskas et al. 1993). Second, HPVs are the most common sexually transmitted
disease. In 1991 a group of Canadian scientists, McNicol and Dodd, used the
polymerase chain reaction to determine the prevalence ofHPV DNA in human prostate
carcinomas. They observed that 52 % of the prostate carcinomas contained HPV-16 and
/or HPV-18 sequences. In another study of Japanese patients with prostate cancer, it was
found that 41 % of tissue samples tested positive for at least one type of the HPVs, with
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the most common being HPV-18 (Sarkar et al. 1993). HPV appears to be commonly
associated with, but not sufficient alone for the development of prostate cancer.
The mammalian ras gene family contains three homologous members: Ki-ras, Ha¬
ras, and N-ras. Each encodes a 21 kDa protein with either 188 or 189 amino acid
residues. Ras proteins switch between an active form that binds GTP (Guanine
triphosphate) and an inactive form that binds GDP (Guanine diphosphate) (Boguski and
McCormick 1993). Activated ras in turn activates serine-threonine kinase raf-l, which
then activates MAP kinase kinases (MEKs) which in turn activate the p42/44MAP
kinases (ERKs). Ras also activates raf-l-independent signaling pathways leading to
activation of c-jun N-terminal kinases (JKN kinases). Oncogenic mutations detected in
Ha-, Ki-, and N-ras genes isolated from different human tumors localized in the N-
terminal (amino terminal) region controlling GTP binding, suggesting that genes become
oncogenic when they remain in the GTP-bound state (Zhongfa et al. 1997).
Recent molecular studies have suggested that ras oncogenes may play a role in
prostate carcinogenesis. Studies have shown that increased expression of the ras p21
protein is associated with increasing histological grade in human prostatic cancer (Viola
et al. 1986; Davies et al. 1988; Sumiya et al. 1990). In addition, several prostate cancer
cell lines have also been shown to express high levels ofHa-ras gene (Rijinders et al.
1985). Because of a possible correlation between ras oncogene with prostate cancer, v-
Ki-ras (viral-Ki-ras) was used to induce transformation of immortalized, non-
tumorigenic RWPE-1 cells to produce tumorigenic RWPE-2 cells (Bello et al. 1997).
The development ofhuman cell models permits studies on the etiology,
progression, and prevention of human prostatic neoplasia and on the identification of
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relevant cellular and molecular alterations in neoplastic processes (Bello et al. 1997).
Hence, these cell lines are the most useful well-characterized human epithelial cell lines
available and served as normal and tumorigenic models for this investigation.
Cell Surface Molecules and Cancer Development
The loss of normal cell organization, cell polarity, and celhcell and celhbasement
membrane (BM) adhesion has been observed in many carcinomas including invasive
prostatic carcinomas and advanced prostatic intraepithelial neoplasia (PIN) (Bostwick,
1992; Rodriguez-Bouclan 1989). Normal expression of the basement membrane protein
laminin and cell adhesion molecules (e.g. cadherins and integrin receptors) for the
extracellular matrix (ECM) proteins (that adhere to the BM) is critical for normal
morphogenesis.
The process of tumor growth and metastasis is a complex cascade of events. For
many of these steps the tumor cells must be able to change their degree of adherence.
Tumor progression and metastatic dissemination are tightly linked with the ability of the
tumor cells to interact with other cells and with the ECM. The first step ofmetastasis is
the active migration of tumor cells into the surrounding tissue (Horn et al. 1996).
Studies have found that laminin receptors are differentially expressed in
tumorigenic cells and their normal counterparts. For instance, it has been demonstrated
that metastatic cells: a) have more receptors for laminin compared with non-tumorigenic
cells; and b) exhibit a second population of low-affinity binding sites not present on non-
tumorigenic cells. The differences in receptor number and type may account for the
greater interaction of tumorigenic cells with laminin and their invasive phenotype (Horn
etal. 1996).
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In 2000, Liu et al. found that the expression of cell surface molecules in cancer cell
lines are differentially expressed and that some prostate cancer cells actually express
antigens that are not usually associated with prostate epithelial cells. In 1997, Zhongfa
et al. found that Ki-ras transformed cells express aberrant forms ofB-1 integrin. This
study showed that altered glycosylation of the B-1 chain of integrin inhibited adherence
and polarization of transformed cells. More recent studies describe the up-regulation of
a non-integrin-laminin-binding protein that has been found to contribute to tumor
invasiveness. For example, cell adhesion assays showed that a 67 kDa laminin receptor
(67LR) acts as an accessory molecule in tumorigenic cells (Ardini et al. 1997). Hence,
these observations suggest that upon transformation, cells adopt an alternative
mechanism of cell attachment and invasion.
Prostate Cancer and Immunotherapy
The general responsiveness of cancer patients to immunotherapy is well
established (McGee 1991). The important role of antibodies in the control of tumor
growth has been demonstrated in passive and active immunotherapy of cancer patients,
using MAbs (Riethmuler et al. 1994), TAA (Livingston et al. 1987), whole tumor cells
(Mitchell et al. 1988), or anti-idiotyic antibodies (Mittelman et al. 1992; Durrant et al.
1994). However, in PCa, the active immunotherapy approach employing TAA has been
hampered by insufficient knowledge ofPCa-associated structures that are immunogenic
in patients. A major focus of cancer immunology is on the isolation of antibodies that
react selectively with human tumor cells because the antibodies could have important
applications for targeting diagnostic and therapeutic agents to tumors and for identifying
tumor-associated antigens for immunization via pharmaceutical targeting (Hellstrom et
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al. 1991). The established approach has been to generate panels ofMAbs from mice
immunized with human tumor cells and to screen the antibodies for reactivity against the
tumor. Despite the enormous effort expended on this approach, few antibodies that react
preferentially with tumor, or specifically with one type of tumor, have been reported
(Hellstrom et al. 1991; LoBuglio et al. 1992; Herlyn et al. 1988; Lloyd 1993). These
results are disappointing but not necessarily conclusive because the antibodies were
generated in a xenogenic (between different species) system. Human antigens are
generally recognized as foreign by themurine system, and because most antigens on
tumor cells are not tumor specific, the murine response to human tumors will be
correspondingly nonspecific. Another approach involves generating human MAbs from
cancer patients by cloning lymphocytes transformed with Epstein-Barr virus or fused
with myeloma or B-lymphoblastoid cells (Haspel et al. 1985; Koda et al. 1990; Hoon et
al. 1993; Ditzel et al. 1993; Hall et al. 1994; Chaudhuri et al. 1994). However, the
number of clones that can be produced with these procedures is severely limited by
technical obstacles, and the antibodies isolated from the clones have shown specificities
similar to those obtained with murine MAbs (Cai and Garen 1995). Other attempts to
isolate more specific antibodies will require improved methods of generating and
selecting antibodies against human tumors. Recently, two developments have shown the
potential in providing those methods. One involves immxmizing cancer patients with
autologous tumor cells that have been genetically modified to boost the immunogenicity
of the cells (Dranoff and Mulligan 1995). The other development is the introduction of
elegant methods for synthesizing virtually the entire repertoire of a person's antibody
genes (antibody library) and for expressing the encoded antibodies on the surface of a
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fusion phage vector (Marks et al. 1991; Barbas et al. 1991). The resulting "fusion
phage" antibody library can be "panned" to select and clone rare antibodies on the basis
of their binding specificities.
Goals of the Study
In the present study, a semi-synthetic phage single chain variable fragment library
(scFv) was assayed for the identification of clones that bind to tumorigenic prostate cells
and not to normal prostate cells. This library was selected because a semi-synthetic
repertoire is not biased by immune selection and therefore may have a broader range of
antibody specificities. The non-tumorigenic cell line, RWPE-1, was used for
subtraction, while the tumorigenic cell line, RWPE-2, was used for selection. These cell




Antibody Structure and Genetics
Virtually any substance can elicit an antibody response. The response to an
antigen (Ag, a molecule to which an immune response is elicited) is diverse, consisting
ofmany different antibody molecules each with a unique affinity and fine specificity.
The complete collection of antibody specificities available within an individual is known
as the antibody repertoire. In humans, the repertoire contains as many as 10* * different
antibody molecules (Janeway 1999).
Antibodies (Abs), which are proteins secreted by B-lymphocytes, are made of two
or more pairs ofheavy and light chains joined by disulfide bonds (Figxne 1). There are
two types of light chains found in human and mouse, which are termed lambda (A.) and
kappa (k) chains. On the other hand, the antibody class is defined by the structure of the
heavy chain. The five major classes are immunoglobulinM (IgM), immunoglobulin A
(IgA),imm;moglobulin D (IgD), immunoglobulin G (IgG), and immunoglobulin E (IgE)
(Janeway 1999).
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Figure 1. Antibody Structure.
Each antibody molecule has a two-fold axis of symmetry and is composed of two
identical heavy chains (~60 kDa) and two identical light chains (~30 kDa). Each chain
has two regions composed of variable and constant regions called the variable heavy
chain (VH)/constant heavy chain (Ch) and variable light chain (VL)/constant light chain
(Cl). The VhA^l domains differ from one antibody to another and contain the antigen¬
combining 3-dimensional structure. The Ag-binding site is composed of six
hypervariable regions called complementarity-determining regions (CDRs) (Wu and
Kabat 1970). Three CDRs from the heavy chain and three CDRs from the light chain
are moimted on more conserved anti-parallel B-sheets that are called framework regions
(FRs). To create the Ag-binding site, the CDRs from the Vh and Vl regions are
juxtaposed at one end of the Ab to form a composite surface (Janeway 1999).
14
The diversity that is necessary to generate Abs that can interact with any antigen
is created by two processes, i.e. combinatorial rearrangement and somatic
hypermutation. Combinatorial rearrangement of gene segments occurs during the early
differentiation of the B cells (Tonegawa 1983). The V domain of the light chain is
produced via the recombination ofVl and joining (Jl) gene segments. The juxtaposition
of these two gene segments encodes the third CDR loop (LCDR3), whereas; the first two
CDRs are completely encoded by the germline Vl segment. The heavy chain Y domain
is formed by the recombination of three gene segments, Vh, diversity (D), and Jh
(Tonegawa 1983). All three gene segments contribute to the germline Vh segment.
Most of the diversity is created in the heavy chain CDR3 region. Recombination is
imprecise and nucleotides can be added or deleted at the junctions of these gene
segments, resulting in a further increase of diversity (Tonegawa 1983).
Somatic hypermutation occurs after antigenic stimulation of the B cell. The
result is the introduction ofpoint mutations in the rearranged variable region genes
leading to higher affinity and more specific Abs. Class switching ofAbs from IgM to
IgG isotype accompanies this process, which is also called affinity maturation. Recent
studies have shown that the diversity introduced by somatic mutations act on
complementary residues of the Ag-binding site to bind and improve Ag recognition
(Tomlinson et al. 1996). The presence ofparticular sequence motifs or "hot spots" that
are preferentially targeted by somatic mutation is partially responsible for this effect
(deWildt et al. 1999; Domer et al. 1997).
Diversity within the antibody repertoire is also achieved by affinity maturation.
Many variable (V)-domain gene segments are present in the genome of an individual.
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and thus provide a heritable source of diversity. Additional diversity results from the
formation of a complete V-region exon by the random recombination of separate V, D
(diversity), and J (joining) gene segments. Variability of the junctions between
segments is increased by random insertion and variable deletion ofnucleotides at the
ends of coding sequences (Janeway 1999).
Antibody Function
The constant regions (Ch, Cl) are essentially invariant within a given antibody
class or subclass, and are responsible for immune system effector frinctions. The
variable region can take an apparently infinite variety of different forms that allow it to
bind specifically to a vast variety of different antigens (Milstein 1986). During immune
response, specific antibodies recognize an antigen. The region of the antibody that is
responsible for Ag binding is defined by the CDRs.
Proteolytic enzymes (proteases) that cleave polypeptide sequences have been
used to determine which parts of the molecules are responsible for its various functions
through structural dissection (Janeway 1999). For instance, digestion ofantibodies with
papain leads to the production of two antigen-binding fragments (Fabs) and one
crystallizable fragment (Fc). The Fab fragments correspond to the arms of the antibody
molecule, which contain the complete light chains paired with the Vh and ChI domains
of the heavy chains. The Fc contains no antigen-binding activity but was originally
observed to crystallize readily. This fragment corresponds to the paired Ch2 and Ch3
domains and is the part of the antibody molecule that interacts with effector molecules
and immune cells (Janeway 1999).
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Genetic engineering techniques have been useful in the production of truncated
antigen binding proteins containing only the V region (Vh and Vl chains) linked by a
flexible linker. This fragment is called the single chain variable fragment (scFv). ScFv
molecules may become valuable tools because of their small size, which allows tissue
penetration. In addition, they may also be coupled to protein toxins to yield
immunotoxins with potential application in, for example, tumor therapy (Janeway 1999).
Hvbridomas and Monoclonal Antibodies
Efforts to identify tumor-associated antigens have historically involved either
polyclonal serum antibodies of experimental animals or patients (Hamby et al. 1987; Old
1981; Hayashibe et al. 1991), ormonoclonal antibodies derived from hybridomas
produced through immunization ofmice with human Ags or live tumor cells. Georges
Kohler and Cesar Milstein (Kohler and Milstein 1975) developed hybridoma technology
in search ofway to produce a homogenous population of antibodies of defined antigenic
specificity. They accomplished this by fusing spleen cells from an immunized mouse to
cells of a mouse myeloma (plasma cell tumor) leading to the production ofhybrid cells
that proliferate indefinitely and secrete Ab specific for the Ag used to immunize the
spleen cell donor (Janeway 1999). The spleen cells provide the ability to make specific
antibody, while the myeloma cells endow the fusion ofproduct with the ability to grow
indefinitely in culture and secrete immunoglobulin continuously. Cell fusion is
accomplished by using polyethylene glycol (PEG). The myeloma cells are selected
beforehand to ensure that they are not secreting antibody themselves and that they lack
the enzyme hypoxanthine: guanine phosphoribosyl transferase (HGPRT). Absence of
HGPRT makes myeloma cells sensitive to the hypoxanthine aminopterin-thymidine
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(HAT) medium that is used to select hybrid cells or hybridomas. The spleen cells
supplies the HGPRT gene, which allows the hybrid cells to survive in the HAT medium.
Only the hybrid cells can grow continuously in culture due to the malignant potential
contributed by the myeloma cells. Hence, unfused myeloma cells and unfused spleen
cells die in the HAT medium. Those hybridomas producing the desired antigenic
specificity are then selected and cloned by growing the cultures from single cells. The
end result of this process is clones, each ofwhich continuously makes the same antibody
molecules, which are called monoclonal antibodies (MAbs).
Although the production ofmonoclonal antibodies has provided useful tools for
the diagnosis and treatment of various diseases, this method has several disadvantages,
which include:
• Labor intensity
• Small size of repertoire sample (<1000)
• Instabilities ofhybridomas/expression problems
• Recognition of intracytoplasmic antigens (cell surface antigens are preferred
for vaccines to induce humoral responses).
The uses ofmolecular biological methods serve as effective routes in getting
around many of these problems. An alternative strategy for the identification of tumor-
associated cell antigens is the antibody phage display approach. This approach has
numerous advantages over the conventional approaches used thus far:
• Up to 10 clones can be readily examined (Barbas et al. 1991) thereby
increasing the diversity ofantibody molecules identified
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• High-affinity clones can be isolated in the absence (Barabs et al. 1991) or
presence (Griffiths et al. 1994) of in vitro affinity selection.
Antibodies are indispensable tools for recognizing and tracking target molecules
in complex mixtures. However, traditional methods for preparing antibodies, such as the
production ofMAb via hybridomas, are cumbersome and labor intensive. As a result,
researchers are working to develop faster and easier ways to capitalize on the target-
recognition qualities of antibodies. Phage display is a relatively new method that
enables researchers to quickly evaluate a huge range ofpotentially useful antibodies and
then produce large quantities of the selected ones. The phage display method used in
this study takes advantage of the properties of filamentous phage Ml 3.
Filamentous Bacteriophage
Filamentous bacteriophages (Genus Inovirus) are a group of bacterial viruses that
contain a circular single-stranded DNA genome encased in a stet protein capsid. Viruses
within this genus infect bacteria via pilus infection. The Ff class of the filamentous
phages (M13, fd, fl, IKe) use the tip of the F conjugative pilus of bacteria as a receptor
and thus are specific for bacteria containing the F plasmid. The Ffphage infection is not
lethal to its host. These single-stranded DNA (ssDNA) of these lysogenic phages is
replicated via a double-stranded intermediate (RF, replicative form) by a mixture of
bacterial and phage-encoded proteins, resulting in newly synthesized viral single-
stranded DNA in a complex with copies of phage-encoded single-stranded-DNA-binding
protein.
The Ff phage particle is approximately 6.5 nm in diameter and 930 nm in length.
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The mass of the particle is approximately 16.3 mDa, ofwhich 87 % is contributed by
protein (Barbas 2001). The genome is a single-stranded, covalently closed DNA
molecule of about 6400 nucleotides that is encased in a flexible protein capsid. The
length of the protein cylinder consists of approximately 2700 molecules of the 50 amino
acid major coat protein, gene F///protein (pVIII). One end of the particle contains 5
molecules of the 33-residue gene F//protein (pVII) and the 32-residue gene IXprotein
(pIX). The other end consists of approximately 5 copies of the 406-residue gene III and
112-residue gene VIproteins (pill and pVI). The DNA is oriented within the virion such
that a 78-nucleotide hairpin region called the packaging signal (PS) is located at the end
of the particle containing pVII and pIX proteins (Barbas 2001).
The genomes of the Ffphage have been completely sequenced (Van Wezenbeek
et al. 1980; Beck and Zink 1981; Hill and Petersen 1982). The genome consists of 11
genes encoding 11 proteins (pI-pXI). Two of these proteins, pX and pXI, are products of
internal translational initiation of gene II and III, respectively (Model and Russel 1988).
The minor coat protein pill of filamentous bacteriophage is essential for infectivity. It
possesses a tripartite structure, in which single domains are separated by glycine-rich
linkers. Crystal structures of the first domains, D1 and D2, have been determined
(Lubkowski et al. 1998; Holliger et al. 1999), demonstrating a horseshoe-like
conformation of the two structurally related domains. The C-terminal domain, D3, is
known to be required for pIII incorporation into the phage particle and release fi'om the
inner membrane (Stengele et al. 1990; Rakonjac et al. 1999). Filamentous phage infect
E. coli by binding ofD2 to the tip of a sex-pilus encoded by the F episome in male
strains. As the pilus retracts to the cell surface, D1 binds to the C-terminal domain
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(TolAIII) of the TolA protein, a subunit of the ToIQRA pore-complex present in the
periplasm (Riechmann and Holliger 1997). Interestingly, pill shares similarities with
colicins such as colicin la in terms of structure and uptake mechanism (Riechmann and
Holliger 1997; Click and Webster 1997). By transferring the major coat protein into the
inner membrane at the ToIQRA complex, the phage genome is released into the
cytoplasm of the cell (Click and Webster 1997). The invading ssDNA is replicated to
many copies of the double stranded replicative form (RF) by involvement of pll. In the
meantime, the remaining phage genes are transcribed and translated. The coat proteins
(pill, pVI, pVII, pVIII and pIX) of the progeny phage accumulate in the iimer
membrane. Finally, the pV determines the switch from RF to the so-called (+)-strand
ssDNA synthesis. The pV- complexed DNA is guided to the morphogenic trans¬
membrane proteins pi, pXI and pIV, where the assembly of the phage particle takes
place. These morphogenic proteins share similarities with other bacterial proteins
involved in protein export, suggesting a related mechanism for the assembly of
filamentous phage and type IV pilus biogenesis (Russel et al. 1997). All five sfructural
proteins of the virus particle are anchored in the inner membrane prior to their
incorporation into phage particles (Endemann and Model 1995). DNA bound pV is
continuously displaced with pVIII, dependent on thioredoxin (Feng et al. 1997). The
morphogenic proteins pl and pXI export the ssDNA, probably by an ATP dependent
mechanism, extruding the newly formed particle into the extra-cellular environment
(Russel et al. 1997; Marvin 1998). Plaques formed by these phages on an E. coli lawn
appear turbid, because the infected bacteria are only impaired in growth but not lysed.
This distinguishes the filamentous phage from most other bacterial viruses which are
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icosahedral in shape, accumulate in the cell cytoplasm and accomplish their release from
the host cell by lysing it.
Recombinant DNA Vectors
All of the coat proteins of the filamentous phage can be fused to foreign proteins
and peptides with varying degrees of success; however, the most common fusions are to
the minor coat protein, pill, or the major coat protein, pVIII. In George Smith’s (1993)
classification of the main types ofphage-display vectors, each type of vector is
differentiated on the basis of (Table 1):
• The coat protein used for display (i.e. pill or pVIII)
• Whether the protein to be displayed can be fused to all copies ofpill or pVIII, or to
only a fraction of them
• Whether the recombinant fusion is encoded on the phage genome or on a separate
genome (e.g., a phagemid).
Phagemid systems offer an alternative to cloning directly into the phage genome and
provide several distinct advantages that are particularly relevant to the display of large
proteins (Barbas 2001).
Table 1. Classification of phage display vectors















Type 3 pill All 1 Phage MBKE"’”
,C
Type 8 pVIII All 1 Phage d
Table 1 - Continued
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Type 33 pill Some 2 Phage e
Type 88 pVIII Some 2 Phage F88-4'’®
Type 3+3 pill Some 2 Phagemid pComb3 ”
pHENl
Type 8+8 pVIII Some 2 Phagemid ij
“Scott and Smith (1990).
‘’Cwdrla et al. (1990).
‘^Kayetal. (1993).
‘^Petrenko et al. (1996).
‘McCafferty et al. (1993). ^Wrighton et al. (1996).
®Haaparanta and Huse (1995). ^Unknown.
*’Barbas et al. (1991).
‘Kang etal. (1991).
Phage Display Systems
In phage-display, peptides or proteins are usually fused to the N-terminus of
either minor coat protein pill ormajor coat protein pVIII. Additionally, cDNA libraries
can be displayed by a fusion to the C-terminus ofpVI (Jespers et al. 1995; Fransen et al.
1999). In a rather recent approach, the N-termini ofpVII and pIX were used as a fusion
partner (Gao et al. 1999), but this has not been extensively explored. Phage particles can
either contain a phage genome, or a "phagemid" which consists of a plasmid carrying the
phage origin of replication and one gene encoding a coat protein fusion when transduced
into E. coli, these vectors replicate as plasmid. The presence of a resistance marker gene
allows for the selection of library-containing bacterial cells for propagation. For
propagation as phage particles, phagemids require the aid of a super-infecting helper-
phage providing all the necessary genes needed for particle formation (but itselfbeing
defective in replication). One resulting difference between phage and phagemid for
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phage-display is the valency of the fusion protein displayed on the surface of the
particle. A phage usually possesses 3-5 copies of the pill and some 2700 copies of the
pVIII coat protein, depending on the length of encapsulated genome (Barbas 2001).
With a phagemid, the promoter preceding the gene can adjust the number of fusion
protein copies per phage particle. There are several advantages for the use of
phagemids, especially if the protein to be displayed is large and/or reduces the infectivity
of the phage particles. This could lead to an accumulation of non-displaying deletion
phage, and loss ofmuch binding specificity, elevating the non-specific background in
the selection process. Depending on the coat protein used as fusion partner and the
choice of the system, different proteins can be effectively displayed. The minor coat
protein pill tolerates N-terminal fusions with random 15 mer peptides (Devlin et al.
1990) or proteins as large as scFv (McCafferty et al. 1990). Many other proteins like
protease inhibitors such as hPSTI (Rdttgen and Collins 1995) and whole enzymes such
as P-lactamase (Soumillion et al. 1994) were displayed on pill using a phagemid system,
alleviating constraints in terms of infectivity, thus leading to a more stable library. This
is even more obvious for the major coat protein, gpVIII (gp, glycoprotein), that tolerates
only the insertion of six N-terminal amino acids due to steric hindrance ofneighboring
fusion proteins (Greenwood et al. 1991). Larger peptides and proteins like Fab, trypsin,
or BPTI were efficiently introduced by the use of hybrid phage producing wild type and
fused protein pVIII or using a phagemid system (Greenwood et al. 1991; Kang et al.
1991; Corey et al. 1993; Markland et al. 1991). Display ofheterologous proteins on
filamentous phage coat proteins is limited to secreted protein variants, which are capable
to adopt a native conformation under the non-reducing conditions of the extracellular
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space. Therefore, cytoplasmic proteins containing cysteine residues in their sequence
are prone to aggregate in the periplasm and will not be translocated along with the phage
particle. There are alternative phage-display systems available employing the X,-phage
or T4-phage, which allow the display of cytoplasmic proteins on the surface (Mikawa et
al., 1996; Ren etal., 1996).
Phage Display Library Construction
Twenty years ago, a novel technique was introduced for the production of
antibody-like molecules. This technique, which was initially introduced in 1985 by G.P.
Smith (Smith 1985), involves the amplification of gene segments encoding the antigen¬
binding regions of antibodies and fusion of their products to coat proteins of filamentous
phage. These gene fusions are used to infect bacteria for the production of phage
particles that express the antibody-like fusion protein, with the antibody-binding domain
on its surface. The resulting collection of recombinant phage is called a phage display
library (Janeway 1999).
Phage display uses bacteriophage to produce and select recombinant antibodies
that have all the molecular target-recognition qualities ofnatural antibodies. In fact,
these recombinant antibodies are produced using the same genes that code for the target
recognition or variable region in natural antibodies from mammalian systems. The
phage is genetically engineered so that a particular antibody is fused to a protein on the
phage's coat and the gene encoding the displayed antibody is contained inside the phage
particle. This technology couples the displayed antibody's phenotype to its genotype,
allovvdng the DNA that code for the selected antibody to be retrieved easily for future
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use. Phage libraries each typically contain millions to billions different antibodies, with
numbers comparable to that in human immime systems (Barbas et al. 2001).
Phage display relies on the ability to clone antibody fragments independently and
randomly recombine them in a system that allows the specificity of binding to be
selected. The current M13 filamentous phage and phagemid vectors enable coupling of
affinity selection (based on the displayed repertoires of Fab and scFv fragments) to the
recovery of the packaged gene encoding that antibody. This system is highly effective
and has been used to isolate human Fab and scFv fragments against a range of cell
surface markers (Hoogenboom et al. 1998; Bradbury 1999; de Haard et al. 1999;
Ridgway et al. 1999) and related proteins that can be targeted for cancer therapy (Pini et
al. 1998). Human antibody genes can be extracted from "immunized" hosts and have the
advantage of already being somatically matured to high binding affinity (Mao et al.
1999). Alternatively, antibody fragments can be selected from very large ‘naive’
repertoires that have been either constructed from germline V-domains or synthesized
with large numbers ofmutations, typically in CDR loops (de Haard et al. 1999; Ridgway
et al. 1999). These antibodies can also be affinity matured, in some cases to exceptional
affinity (Adams et al. 1998).
The phage display process is accomplished in several steps, starting with the
reverse transcription ofmRNAs and subsequent PCR (Polymerase Chain Reaction)
amplification of the resulting cDNAs encoding the V domains of the heavy and light
chains expressed in the B cells of an individual. All human germline V, D, and J gene
sequences have been characterized and a comprehensive database is available
(http://www,mrc-cpe.cam.ac.uk/imt-doc/index.html; Tomlinson et al. 1999). Based on
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this database, primer sets have been developed in order to amplify nearly all members of
the different heavy and light chain gene segments, avoiding any substantial bias at this
stage. Isotype-specific constant region primers are then used to restrict the library to a
particular isotype (Marks et al. 1991). The amplified repertoire ofV regions is then
cloned into a filamentous phage vector (e.g. pHENl) resulting in fiision ofV regions to a
gene encoding one of the coat proteins (i.e. pill or pVIII). This vector is then used to
transform bacterial cells (e.g. XL-lBlue, TGI). One phagemid, carrying one set ofAb
genes, enters each cell during this process. The phagemid genome contains the
filamentous phage intergenic region with its origin of replication for viral and
complementary strand synthesis as well as the hairpin packaging signal (Bass et al.
1990; Breitling et al. 1991). The phagemid also contains a plasmid origin of replication
and a gene encoding resistance to a specific antibiotic, e.g. ampicillin (Barbas et al.
2001). Bacterial cells carrying the phagemid are selected by growth on medium
containing ampicillin; only the phagemid, and not the bacterial chromosome, carries a
gene for ampicillin resistance (P-lactamase). Chimeric genes encoding antibody-phage
protein fusions are placed under the control of a specific promoter in these phagemid
genomes. There, following induction of transcription of the fusion proteins it is capable
ofproducing Ab fragments that assemble in the periplasm of the cell anchored in the
inner membrane of the bacteria.
The next stage is the rescue of the phagemid DNA by adding infective “helper
phage” to the cells. In a complex process, the helper phage enters the cell and packages
the DNA from the phagemid (carrying antibody genes) in preference to its own. As it
leaves the cell, the phage is capped at one end by 3-5 molecules of coat protein III (pill).
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Since some of the pill molecules are linked to the antibody fragments, a typical phage
will carry one Ab molecule on its surface and the corresponding genes inside. When this
process is applied to a library of phagemids, it generates a library of recombinant phage
and amplifies the initial library so that typically -10“* copies of each phage (antibody
genes) are generated (Burton 1991).
Expression of the Ab fragment as a fusion product and its incorporation into the
phage results in the Ab fragment being presented on the surface of the phage, while its
DNA is packaged within the phage particle. During cloning procedures of these
libraries, the Vh and Vl genes are randomly recombined. Henee, the recombinant Abs
do not usually reflect the original VhWl pairings present in the B cell.
Phage Display Antibody Librarv-Biopanning
Biopanning is an in vitro selection process that allows rapid identification of
protein ligands for a variety of target molecules (such as antibodies, enzymes, cell
surface receptors, etc.) (Schumacher et al. 1996; Goodson et al. 1994; Barry et al. 1996;
Parmely and Smith 1988). Biopemning has typically been performed by incubating a
large random library of unselected phage-displayed peptides or proteins with a
polystyrene plate coated with a target molecule. After washing, some proteins stick to
the target and remain bound; these may be high affinity interactions. Specifically bound
phages remain and are released by elution via acid or enzymatic treatment. The eluted
phages are then amplified in bacteria, collected, and used to run additional
binding/amplification cycles to enrich the pool ofbinding clones. Individual clones can
then be tested for binding to the target Ag, and subsequent clones can be produced as
soluble Ab fragments. The genes encoding Vh and Vl can be cloned either as Fab
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fragments, which contain additional constant domains fused to each of the variable
domains, or as scFvs in which the two variable domains are connected by a flexible
(glycine-serine) rich linker. Both types of recombinant Abs form functional monovalent
derivatives ofAbs.
In vivo the B cell contains the rearranged immunoglobulin genes encoding the
Ab that is displayed on its surface. An encounter with Ag causes B cells to proliferate
and differentiate into Ab secreting plasma cells. This is an Ag stimulated selection,
hence some aspects of the phage display process have similarities with the normal
immune response (Winter et al. 1994; Burton and Barbas 1994).
The phage clones are also used for in vitro binding affinity assays with the
original target. Enzyme-linked immunosorbent assay (ELISA) is widely used for
detection ofAg binding affinity in the phage display library screening, with the detection
level being as low as lO'^g for protein Ags (Hoess et al. 1994). The method is to fix the
specific target protein on the supporting surface and add the selected Abs, (e.g.
periplasmic extracts containing single chain variable fragments). Repeated washings
then remove nonspecifically bound protein. The remaining protein is eluted by acid or
excess soluble antigen. A round ofpanning generally produces an enrichment factor for
specific phage on the order of 100. Repeated panning should sufficiently extract specific
phage occurring only singly in the initial library. Finally, the specific recombinant
phage are converted to the phagemid form that when inserted into either a suppressor
(expressing glll/antibody fusion protein) or non-suppressor strain (expressing soluble
antibody fragments) bacterial cells replicate as plasmids in the absence of helper phage.
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Phage antibody display technology offers a powerful tool for the isolation of
specific antibodies to defined target antigens. Most selection strategies to date have
relied on the availability of purified and recombinant antigen, providing the possibility to
perform selections on a well-defined antigen source. However, when the target antigen
cannot be purified, or if the antigen is unknown, panning of phage antibody libraries has
to be performed on complex antigen sources such as cell surfaces or tissue sections
(Mutuberria et al. 1999).
In the last few years, a number ofnew selection strategies have been developed.
For example, target molecules are either directly coated to a solid surface or the protein
is captured after binding to a phage library in solution. Selection with Ag in solution is
performed by using biotinylated Ag followed by capture to streptavidin beads or capture
of the Ag to an immobilized MAb. More advanced and correspondingly difficult
methods include selection using membrane-associated proteins, purified cells and whole
tissues (Van Ewijk et al. 1997). Through the use of these methods, Abs directed to
particular Ags, such as MHC-peptide complexes (Andersen et al. 1996) and human
blood group Ags (Marks et al. 1993) have been isolated. In the case of eukaryotic cells,
depletion or subtraction strategies with non-target cells have been performed. This
method has been used to isolate Abs against TAAs (Cai and Garen 1995; Shukla 2005)
and new lymphoid cell markers (Hoogenboom et al. 1998).
The outcome of selections on complex antigens is governed by a number of
parameters that can roughly be divided into antigen-related factors and selection-related
factors. Important antigen-related factors include the amount (concentration) of antigen,
the quality of the antigen (integrity during selection procedure), the nature of the antigen
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(internalization, accessibility, glycosylation, presence of immunodominant epitopes,
expression profile on different cell types, environment-dependent expression) and
generation ofneo-epitopes due to preparation of the antigen. Selection-related
parameters include the phage library used (i.e, V-gene source of the library, antibody
display format, size of library, etc.), method ofphage preparation, conditions and time of
incubation ofphage with the antigen, blocking and washing during selection, method of
elution and the use of subtraction, and depletion strategies or 'directed'-selection
procedures (Barbas 2001).
Antibody Engineering
Phage display Ab libraries can either be immune, naive (derived from a non-
immunized donor), or semi-synthetic (germline V segments with synthetically
introduced CDR3s). The primary or naive Ab repertoire in an animal consists mainly of
IgM Abs that are able to recognize a variety ofAg. A few naive or IgM libraries have
now been generated from different tissues ofnon-immunized donors and these have
been used successfully to isolate Abs against various Ags including self-Ag (Little et al.
1999). Recently, one technique to produce even more diverse Ab phage libraries (3 X
lO’ * clones) has been reported (Sblattero and Bradbury 2000). Many of these libraries
consist of germline V segments in which the CDR3 loop of the heavy chain is targeted
for diversification.
A new wave ofAbs and Ab fragments is about to enter the clinic for cancer
dit^osis and therapy, and the term “engineered antibodies” has been embraced by the
general public for the first time (Farah et al. 1998; Hudson 1998). These recombinant
antibodies are based on fusion ofmurine variable fragments onto human frameworks
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(Hudson 1998; Dall’Acqua and Carter 1998; Leget 1998). Others are cleverly designed
resurfacing mimne antibodies; for example, murine CDR loops have been grafted onto
human antibody frameworks (Dall’Acqua 1998; Goldberg 1999). The most spectacular
examples of effective cancer treatment using recombinant antibodies that have recently
been approved by the Food and Drug Administration (FDA) include ‘Rituxan’ (IDEC
Pharmaceuticals Inc., San Diego, CA) and ‘Bexxar’ (Beckman Coulter Inc., Fulleron,
CA), both targeting CD20 for therapy of non-Hodgkin’s lymphoma (Leget 1998;
Goldberg 1999).
Display on filamentous phage in combination with selection forms a powerful
tool for the identification ofpeptide- or protein-based drugs (Winter et al. 1994;
Clackson and Wells 1994). In particular, the use ofpartially or completely human
antibodies, which should elicit no or minimal immune response when administered to
patients, is yielding an increasing list ofFDA-approved protein-based drugs (Holliger
and Hoogenboom 1998).
The key to the success of this technology is based on two critical factors: (i) the
expression of functional antibody fragments by secretion into the periplasm ofE. coli
(Better et al. 1988; Skerra and Pluckthun 1988), and (ii) the rapid access to variable
region gene pools by the polymerase chain reaction (Larrick et al. 1989; Ward et al.
1989; Marks et al. 1991). For the construction of the antibody libraries, V-genes are
amplified from B cell cDNA and heavy and light chain genes are randomly combined
and cloned to encode a combinatorial library of scFv fragments. The natural primary
(unselected) antibody repertoire within B cells contains a large array ofantibodies that
recognize a variety of antigens; this array can be cloned as a "naive" repertoire of
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rearranged genes by harvesting the V-genes from the IgM mRNA of B cells of
unimmunized human donors isolated from peripheral blood lymphocytes (Marks et al.
1991), from bone marrow or tonsils (Vaughn et al. 1996), or from similar animal sources
(Gram et al. 1992). This procedure provides access to antibodies that have not yet
encountered antigen, although the frequency of those genuine "germline" antibodies will
depend on the source ofB cells (Klein et al. 1997). A single naive library can be used to
generate antibodies to a large panel of antigens, including self, non-immunogenic, and
relatively toxic antigens (Marks et al. 1991; Griffiths et al. 1993). In a different
approach, in vitro assembly ofV-gene segments and D/J segments, yielding "synthetic"
antibodies (Nissim et al. 1994) may build antibodies artificially.
Technology for antibody design has taken strides forward and new library-display
and -selection procedures have conceptually made classical hybridoma technology
obsolete (Hoogenboom et al. 1998; Bradbury 1999). It is now possible to select high-
affinity antibody fragments directly from a bacteriophage culture rather than from a live
mouse. One significant advantage of this new technology is the isolation of antibodies
with new binding specificities against hitherto refractory antigens, thereby avoiding the
limitations inherent in the mammalian immune response (de Haard et al. 1999; Ridgway
et al. 1999). Antibodies are still the paradigm for the design ofhigh-affinity, protein-
based binding reagents. In recent years recombinant antibodies have been reduced in
size, dissected into minimal binding fragments and rebuilt into multivalent, high-avidity
reagents (Hudson 1998; DalTAcqua 1998). Antibody fragments have also been fused
with a range ofmolecules limited only by the imagination—including enzymes for
prodrug therapy, toxins for cancer targeting, viruses for gene therapy, cationic tails for
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DNA delivery, liposomes for improved drug therapy and biosensors for real-time
detection of target molecules (Barbas 2001).
Over the years, novel combinatorial techniques have been developed to select
individual interacting partners from an enormous diversity ofmolecules. In general, two
approaches can be discriminated. The so-called “rational” design, which relies on data
provided by the constantly growing number of already identified interactions, and the
empirical approach - screening for possible binding partners. The latter is mainly
limited by the diversity of the combinatorial library screened, which represents the so-
called “sequence-space”. The greater the diversity of the library, the more likely it will
contain an avidly binding molecule displaying the desired properties. Such
combinatorial libraries can either be composed of synthetic molecules or consist of
replicating organisms such as viruses or cells. Examples are the oriented synthetic
peptide libraries, the yeast two-hybrid system, a novel bacterial two-hybrid system and
bacterial surface display (Frank 1992; Allen et al. 1995; Karimova et al. 1998; Stahl and
Uhlen, 1997). Exceptions are aptamer and ribosomal-display libraries (Gold et al. 1995;
Hanes and Pluckthun 1997), allowing both screening and amplication in vitro. For the
identification ofvariants in synthetic libraries, a sufficient number ofmolecules have to
be recovered from the screening process. This limits the feasibility of such a library to
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diversity up to 10 individual variants in one ml.
Phage display technology is currently the most powerful in vitro method for the
selection ofhigh-affinity recombinant fragments (Hoogenboom et al. 1998; Bradbury
1999; de Haard et al. 1999; Ridgway et al. 1999). In order to cover a larger “sequence
space”, phage-display offers the most powerful option. It employs the use of
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filamentous Ml 3 bacteriophage. The advantage of the libraries is the physical coupling
ofphenotype and genotype. This enables the identification of a single binding molecule,
displayed as protein or peptide fused to the surface of a bacteriophage by recovery of the
gene in E. coli and sequencing the encoding genome after amplification. Up to 10 Ml 3
bacteriophage can be contained in one ml. Therefore, library size is primarily limited by
the efficiency of transformation ofE. coli enabling realistic if labor intensive library
sizes up to lO" different variants (Collins, 1997).
Recombinant antibodies have been displayed on filamentous bacteriophage
(McCafferty et al. 1990), lytic phage (Forrer and Jaussi 1998), bacteria (Daugherty et al.
1998), yeast (Kieke et al. 1997), and ribosomes (Hanes and Pluckthun 1997) and may be
linked to DNA in the droplets of an emulsion (Tawfik and Griffiths 1998). All these
systems share the underlying principle of linkage between phenotype and genotype,
enabling multiple rounds of selection on immobilized antigen followed by proliferation
to identify specific binding antibodies from a large pool of non-binding antibodies. This
process closely mimics in vivo selection of antibodies in the human immime system.
Many of the large phage libraries that are now available have been used to select binders
to almost any given antigen. These so-called ‘single-pof antibody libraries have been
constructed either by PCR amplification ofnaturally rearranged genes (Marks et al.
1991; Vaughn et al. 1996; Sheets et al. 1998; De Haard et al. 1999), PCR assembly of
germline genes (Hoogenboom and Winter 1992; Akamatsu et al. 1993; Nissim et al.
1994; De Kruif et al. 1995), or by the targeted diversification of specific residues in
well-expressed and well-folded antibody frameworks (Knappik et al. 2000; Pini et al.
1998). Such libraries are typically between 10’ and 10'^ clones in size. Larger libraries
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(in excess of members) have also been generated by Cre-lox-mediated
recombination (Sblattero and Bradbury 1998; Griffiths et al. 1994). Phage-antibody
libraries have so far yielded antibodies to several hundred targets, including cell-surface
markers (Sheets et al. 1998; De Haard et al. 1999; De Kruif et al. 1995; Van Der Vuurst
and Lotenberg 1999), peptide hormones (Vaughn et al. 1996; De Haard et al. 1999),
other human proteins (Griffiths et al. 1994; Griffiths et al. 1993; De Wildt et al. 1996)
and carbohydrates and small molecules (Dinh et al. 1996; Mao et al. 1999). Several
selection strategies are currently being adapted to enable phage-antibody technology to
be applied to proteome- wide selection ofmonoclonal antibodies against a wide range of
targets: selection on complex antigen; conventional but highly parallel selection; and
library versus library selection. The first approach involves the simultaneous selection
ofmany antibodies against complex antigens, such as whole cells, cellular extracts or
tissue sections. This has the potential to generate an extensive panel of antibodies that
could, if desired, be tissue-type specific. Inherent biases in phage selection, however,
generally lead to the isolation of one or a small number of antibodies against the most
abundant protein and not a wide diversity of binders to all targets in the mixture
(Hoogenboom et al. 1999).
Application ofRecombinant Antibodies
Recombinant antibodies identified using in vitro selection technologies are ideal
for analyzing the proteome of a cell. They are not only highly specific (as demonstrated
by their utility in immunohistochemical staining) but can give a very sensitive readout of
the relative abundance of a given protein in a cell lysate. Such semi-quantitative
detection can be performed either by Western blotting or by flow cytometry of labeled
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cells. By using different antibodies, each directed against a different cellular protein, the
levels of all of these proteins could be monitored simultaneously. For a handful of
antibodies this could be achieved by performing separate Western blots or flow
cytometry experiments, or perhaps by mixing antibodies labeled with different
fluorescent tags. In order to monitor thousands of interactions, however, thousands of
different antibodies would need to be screened for binding to components present in, for
example, a fluorescently labeled lysate. Arraying the antibodies and performing parallel
screens using the same antibody array on different tissues should be possible to identify
antibodies that bind differentially expressed proteins, even when the identities of the
individual proteins are not known. Thus, antibodies selected against a diseased tissue
could be screened in parallel against diseased and non-diseased tissues. Those
antibodies that bind components present in one and not the other would then be used to




The recombinant scFv library used consisted of a 1:1 mixture ofthe Tomlinson I
and J libraries. Both libraries are based on a single human framework Vh (V3-23/DP-47
and JH4b) and Vjc (012/02/DPK9 and JkI). Library I contain DVT, where D represents
an equal amount of the nucleotides A, G, and T, V represents an equal amount of the
nucleotides A, C, and G; and T. Library J contains NNK, where N represents equal
amounts ofA, C, G, and T, and K represents equal amounts of the nucleotides G and T.
DVT and NNK were incorporated at positions in the antigen-binding site that make
contacts to antigen in known cocrystal structures and are highly diverse in the mature
repertoire (18 different amino acid positions in total) (Nissim et al. 1994). The
respective library sizes are 1.47 x 10^ (DVT encoded-Library I) and 1.37 x 10* (NNK
encoded-Library J). The expression vector used (pIT2) is derived from pHENl
(Hoogenboom et al., 1991) and contains a lac promoter and a pel B leader sequence
upstream of the Vh-(G4S)3-Vl insert, which is then followed by Hise and myc tags, an
amber stop codon and the gene encoding the pill phage coat protein. Thus, in a suitable
suppressor strain (XL-1 Blue), addition of ispropyl-thio-B-galactosidase (IPTG) induces
expression ofboth scFv-pIII fusion and scFv and their transport to the plasma membrane
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Cell Lines and Antibodies
Prostatic cell lines RWPE-1 and RWPE-2 (American Type Culture Collection)
were maintained in Keratinocyte Serum-Free Media supplemented with 50 pg Bovine
Pituitary Extract/mL (BPE), 5 ng Hiunan Epidermal Growth Factor /mL (EGF),
Fungizone, and antibiotic/antimycotic mixture (Bello et el. 1997). Both cell lines were
grown at 37 °C in 5 % CO2 /95 % air incubator.
Preparation of scFv Clones
Stocks of Tomlinson libraries J and I were each inoculated into 30 ml Super
Broth containing 100 pg ampicillin/ml. After one hour, lOOpl helper phage VCSM13
(Stratagene, ~ 5 x lO" pfu Polyethylene glycol [PEG]-precipitated stock) was added to
2 ml aliquots of Tomlinson I and J cultures and incubated 15 minutes without shaking at
room temperature to allow infection. The culture was then incubated at 30 °C with
shaking for 2.5 hours. Finally, kanamycin sulfate was added to 75 pg/ml and cultures
were induced with 1 mM IPTG and grown overnight at 30 °C with shaking.
Phage Precipitation (Protocol 1)
Thirty-milliliter overnight bacterial cultures were harvested by centrifugation at
10,000 X g in a Beckman JA-20 rotor for 15 minutes at 4 °C. The supernatant was
transferred to a clean 50 ml centrifuge tube and 5 ml of 4% (w/v) PEG/NaCl was added
and incubated for 20 minutes on ice. The mixture was centrifuged at 9,000 g for 15
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minutes at 4 °C. The supernatant was discarded and the phage pellet was resuspended in
4 ml RPMI 1640 media, 10 % fetal bovine serum (FBS), 4 mM PMSF, 0.05 % NaN3,
and 1 % NFDM.
Phage Titer Procedure
To determine cfu/ml (colony-forming units, which represents the number of
infective phagemid particles), serial dilutions of phages (from 10’^ to 10'^^) were made in
IX PBS. Serial dilutions of phage from binding subtractive selection were added to 100
pi exponentially growing XL-1Blue cells and incubated at room temperature for 15
minutes. The samples were plated on L-agar plates containing 100 pg ampicillin/ml and
incubated overnight at 37 °C. The next day, colonies were counted and phage titers were
calculated according to the formula; cfu/ml = #colonies x reciprocal of dilution factor.
Absorption Against RWPE-1 Cells (Protocol 1)
RWPE-1 cells were grown to confluence in T75 tissue culture plates or 6-well
plates, fixed with 100 mM sodium phosphate, pH 6.8 and 2% glutaraldehyde at room
temperature in a fume hood for 20 minutes. The cells were blocked with 4 ml (1/3
volume) RPMI 1640 10 % FBS + 1 mM PMSF + 0.0 5% NaNs. Phages (~10‘^) blocked
in 4 ml RPMI 1640 media, 10 % fetal bovine serum (FBS), 4 mM PMSF, 0.05 % NaNs,
and 1 % NFDM were added to RWPE-1 cells and incubated with gentle agitation for 2
hours at room temperature. The supernatant was removed and the unabsorbed phages
were panned against RWPE-2 cells.
Panning Selection on RWPE-2 Cells (Protocol 1)
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The prostate cell line RWPE-2 was grown as an attached monolayer on T75 flasks
until almost confluent, washed with PBS, and fixed with 2 % glutaraldehyde for 20
minutes in a fume hood at room temperature. The fixed cells were washed with PBS and
blocked with 4 ml (1/3 volume) RPMI1640 10 % FBS + 1 mM PMSF + 0.05 % NaN3.
Resultant non-binding phages from preabsorption were added to confluent RWPE-2
cells and incubated with gentle agitation at room temperature for 2 hours. Unbound
phages were removed by washing five times with 10 ml RPMI 1640 media/10 % FBS
(fetal bovine serum) and IX PBS. Bound phages were eluted with 900 pi 0.25 %
trypsin for 10 minutes at 37 °C. Two millimolar PMSF and FBS (to 10 %) was added
and a portion of the resulting eluate was titered on XL-1 Blue cells on L-agar plates
containing 100 pg ampicillin/ml. The rest of the eluates were used to infect
exponentially growing XL-1-Blue cells as described previously and incubated at room
temperature for 15 minutes. Phages were prepared and titered. The resulting phages
were subjected to two additional rounds of preabsorption/paiming selection cycles.
After two additional rounds, individual XL-1 Blue phagemid transfectants were grown
as clones to test binding activity.
Growing the Libraries (Tomlinson Protocol)
The library stocks were grown in 200 ml pre-warmed 2X TY containing 100 pg
ampicillin/ml and 1 % glucose shaking at 37 °C until the OD 600 read 0.4. Next, 2 x
10" KM 13 helper phage was added to 50 ml of the culture and the culture was allowed
to incubate without shaking in a 37 °C water bath for 30 minutes. The culture was
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centrifuged at 3,000 x g for 10 minutes and the pellet was resuspended in 100 ml of 2X
TY containing 100 pg ampicillin /ml, 50 pg kanamycin /ml, and 0.1 % glucose and
incubated overnight shaking at 30 °C. The next day, the culture was centrifuged at 3,300
X g for 30 minutes. Twenty milliliters ofPEG/NaCl (20 % Polyethylene glycol 6000,
2.5 M NaCl) was added to 80 ml supernatant. The solution was mixed well and left on
ice for one hour. The mixture was then centrifuged for 30 minutes at 3,300 x g and the
PEG/NaCl was discarded. The remaining dregs of PEG/NaCl were removed by a brief
centrifugation. The remaining pellet was resuspended in 4 mL PBS and centrifuged at
11,600 X g for 10 minutes in a micro centrifuge to remove any remaining bacterial
debris. The remaining 150 ml of culture was grown for an additional 2 hours with
shaking at 37 °C. The culture was centrifuged at 10,800 g for 10 minutes, resuspended
in 10 ml of2X TY containing 15% glycerol and stored as a secondary stock in 500 ml
aliquots at -70 °C.
Subtractive Panning Selection (Tomlinson Protocoil
Phage (~10‘^ cfu, colony forming units) were block with 2.5 ml 2 % MPBS at
room temperature rotating on an under-and-over turntable for an hour and allowed to
stand for an additional hour. RWPE-1 cells (5xl0’) were added to the blocked phage and
gently mixed at room temperature for 30 minutes. The cells were pelleted
at 500 X g for 5 minutes at 4 °C and the supernatant transferred to a fi-esh pellet of 3 x
10 RWPE-1 cells and incubated at room temperature for an hour on an over-and-under
turntable. The library was depleted two more times and added to 5 x 10^ RWPE-2 cells.
The cells/library were incubated for an hour at room temperature with gentle mixing.
The cells were pelleted and washed with IX PBS by centrifugation at 500 x g 5 minutes.
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The bound phage was eluted by adding trypsin-PBS (lOpl: lOmg/mL trypsin stock plus
900 pi IX PBS). The mixture was rocked for 10 minutes at room temperature. After
incubating, the cells were pelleted at maximum speed for 1 minute. Logarithmically
growing TGI cells (OD 600 of 0.4) were added to 500 ml of the eluate and incubated in
a 37 °C water bath for 30 minutes. The phage were titred by spotting 10 pi, 10 pi
(1:100) and 10 pi (1:1000) on TYE plates containing 100 pg ampicillin/mL ampicillin
and 1 % glucose and grown overnight at 37 °C. The remaining culture was centrifuged
at 11,600 X g for 5 minutes and resuspended in 1 ml 2X TY and plated on a large
BioAssay plate containing TYE, lOOpg ampicillin /ml and 1 % glucose and grown
overnight at 37 °C.
Propagation of Phase from Subtractive Panning Selection (Tomlinson Protocol)
The cells on the BioAssay dish were loosened in 7 ml 2X TY/15 % glycerol with a
metal spreader. Ten microliters of the cells were inoculated into 10 mL of2X TY
containing 100 pg ampicillin /ml and 1 % glucose. The remaining bacteria were stored
at -70 °C. The 10 ml culture was grown with shaking at 37 °C until OD600 was 0.4.
The entire culture was inoculated with 5 x 10*° helper phage KM13 and incubated
without shaking in a 37 °C water bath for 30 minutes. The culture was centrifuged at
3,000 x g for 10 minutes and the pellet was resuspended in 50 ml 2X TY containing 100
pg ampicillin/ml, 50 pg kanamycin/ml, and 0.1 % glucose and grown overnight at 30 °C
with shaking. The overnight culture was centrifuged at 3,300 x g for 15 minutes and 10
ml PEG/NaCl (20 % PEG; 2.5 M NaCl) were added to the supernatant, mixed, and
placed on ice for 1 hour. Next, the sample was centrifuged at 3,300 x g for 30 minutes
and the PEG/NaCl was poured off. Remaining PEG/NaCl were removed by repeating
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centrifiigation. The resulting pellet was resuspended in 2 ml IX PBS and centrifuged at
11,600 X g for 10 minutes in a micro-centrifuge to remove the remaining bacterial
debris. The phages were stored at 4 °C until the next 2 rounds.
Preparation of scFv Lvsate (Protocol 1 i
Bacteria were grown with shaking overnight at 37 °C in 3 ml Luria broth (LB)
containing 100 |ag ampicillin /ml and 1 % glucose. Next, the overnight cultures were
diluted 1:100 in LB containing 100 |ag ampicillin/ml and grown for 6 hours at 37 °C.
After 6 hours, IPTG was added to a final concentration of 1 mM and the cultures were
incubated with shaking overnight at 30 °C. The bacterial cultures were pelleted by
centrifugation at 11,000 rpm for 5 minutes and pellets were resuspended in SOOpl IX
TBS containing 4 mM PMSF. The resuspended pellets were frozen in liquid nitrogen
for 5 minutes and thawed at 37 °C for 5 minutes. This was repeated five times. After
the last freeze/thaw cycle, the lysates were centrifuged at 11,000 rpm (revolutions per
minute) for 10 minutes to remove cellular debris and supernatants were retained.
Preparation of scFv Lvsate (Tomlinson Protocol)
Clones were picked and inoculated into 150 pL 2X TY containing 100 mg/mL
ampicillin and 1 % glucose in 96-well U-bottom culture plates. The plates were grown
with shaking overnight at 37 °C. The cultures were induced by adding 50 pL 2X TY
containing 100 pg ampicillin/mL and 1 mM IPTG and grown with shaking overnight at
30 °C. The next day, the cultures were centrifuged at 3,000 rpm for 30 minutes. The
supernatant was removed and 200 pL of IX PBS containing 50 pg/mL lysozyme were
added. The plates were freeze/thawed by placing them at -70 °C for 30 minutes and
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37 °C for 10 minutes. The freeze/thaw lysis was repeated 5 times. After the fifth thaw,
the plates were centrifiiged at 3,000 rpm for 30 minutes and the supernatant was
transferred to a new 96-well U-bottom plate. The plates were stored at 4 °C.
ScFv binding bv ELISA (Enzyme-Linked Immunosorbent Assay)
Prostate cells were grown on ninety-six well polystyrene microtiter plates until
confluent, washed 3 times with IX PBS (Phosphate Buffered Saline, buffer), and either
fixed with 2 % glutaraldehyde or not fixed. Endogenous peroxidase activity was blocked
with 0.5 % H2O2 in IX PBS for 20 minutes at room temperature. After H2O2 treatment,
the cells were washed twice with ddH20 (deionized, distilled water). The cells were
blocked with 5 % nonfat dry milk in IX PBS for an hour at room temperature. Fifty
microliters of bacterial lysates containing scFv from round three panning were added
and incubated at room temperature for an hour. After incubating, unbound scFv was
removed and the cells were washed 3 times with PBS 0.1 % TWEEN 20. Fifty
microliters of 9E10 monoclonal antibody at a 1:1000 dilution in PBS were added to each
well and incubated for 1 hour at room temperature. The cells were washed as
previously described and goat anti-mouse IgG Fc horseradish peroxidase (goat-anti-
mouse-Fc HRP) conjugated antibody was added at a 1:1000 dilution in IX PBS to each
well and incubated for an hour at room temperature. Finally, the plates were washed
with PBS/0.1 % TWEEN 20 six times. Peroxidase activity was visualized by adding 50
pi of substrate solution TMB (3,3, '5,5'-tetramethylbenzidine in dimethyl sulphoxide,
Sigma). The reaction was stopped with the addition of 50 pi IM sulfiiric acid. The
microtiter plate was read at either A405 or A450 on amicroplate reader. Negative controls
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were prostate cells only, empty wells, 9E10 MAb + cells, goat-anti-mouse FC-HRP +
cells, and 9E10 MAb + goat-anti-mouse-HRP + cells.
The above steps were repeated using protein L-HRP (1 ;4000) antibody. In these
assays, the controls used were prostate cell plus buffer, buffer only, protein L-HRP only,
Hb-5 (anti-hemoglobin scFv) plus secondary, XL-1 Blue lysate only, XL-1Blue lysate
plus secondary antibody, secondary antibody only, GFP 17 (anti-green fluorescent
protein) plus secondary antibody, TGI lysate only, and TGI plus secondary antibody. In
these experiments, IX PBS was used for dilutions and washings.
DNA Isolation from scFv Clones
Plasmid DNA was isolated from bacterial clones using the Promegamini prep
kit. Briefly, individual colonies were picked and grown with shaking overnight at 37 °C
in 3 /ml Luria broth (LB) containing 100 pg ampicillin/ml and 1% glucose. Cultures
were centrifuged at 11,000 x in a microftige for 2 minutes. Supernatants were
discarded and pellets were resuspended in 200 pi resuspension buffer (Promega). Two
hundred microliters of cell lysis buffer were added and tubes were inverted 5 times.
Neutralization buffer (Promega) was added and the samples were inverted 5 times and
centrifuged at 11,000 x g for 2 minutes in a microfuge. The cleared lysates was then
applied to microspin columns containing 2 ml resin (Promega) and filtered through with
a vacuum manifold. The columns were washed with IX wash solution (Promega) and
centrifuged at 11,000 x g for 2 minutes in a microfuge. DNA was eluted with the
addition of 50 pi ddH20 and centrifugation at 11,000 x g for 2 minutes in a microfuge.
Samples were stored at -20 °C.
Restriction Analysis of scFv Clones
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The scFv inserts were double digested from the vector by treatment of 100 ng
DNA with restriction endonucleases with lU ofSfil and Notl for 3 hours at 37 °C and
50 °C, respectively. Resulting fragments were separated on a 1 % agarose gel
containing ethidium bromide and viewed on a UV-light box.
Purification of scFvs on a Nickel Column
Bacterial lysates prepared by freeze/thaw lysis were used to purify scFvs. Before
purification on the Ni-NTA column (Qiagen), the columns were equilibrated with 600 pi
lysis buffer (50 mM sodium phosphate, 300 mM NaCl, 10 mM imidazole, pH 8.0) and
centrifuged at 700 x g for 2 minutes. The cleared lysates were added to the columns and
centrifuged at 700 x g for 2 minutes and the flow-through was collected. The columns
were washed twice with 600 pi wash buffer (50mM sodium phosphate, 300 mM NaCl,
and 20 mM imidizole, pH 8). Purified scFvs were twice eluted with the addition of 200
pi elution buffer (50 mM sodium phosphate, 300 mM NaCl, 250 mM imidazole, pH 8.0)
by centrifugation at 700 x g for 2 minutes and stored at -20 °C.
Western Blot Analysis of scFv Clones
Proteins from freeze/thaw lysis were separated by SDS-PAGE. The gel used for
separation was 12 % polyacrylamide. The proteins were subjected to a constant current
of 20 nxA for 45 minutes. Once the proteins were separated, they were transferred to
0.45-pm pore size nitrocellulose (Pierce) presoaked in transfer buffer (193 mM
glycine/25 mM Tris/20 % methanol/0.05 % SDS) and transferred at 10 volts for an hour
using a BioRad Transblot semi-dry unit. All subsequent steps were performed at room
temperature on an orbital shaker. Filters were blocked in 5 % non-fat dry milk in IX
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TBS for an hour. The wash solution was removed and undiluted scFv lysates were added
and incubated for an hour. Filters were washed three times for 10 minutes each time in
IX TBS/0.1 % Tween 20, and incubated with 9E10 MAb (1:1000 dilution in IX TBS)
for an hour. The filters were washed as previously described and incubated with goat-
anti-mouse Fc horseradish peroxidase (1:1000 dilution in IX TBS) for an hour. Filters
were washed in IX TBS/0.1 % Tween 20 and developed using DAB (diaminobenzidine)
substrate (Pierce). A kaleidoscope marker was used as a molecular weight standard
(Sigma-Aldrich).
DNA Sequencing
PCR amplification and sequencing of scFv clones were performed using the
primers LMB3 (CAG GAA ACA GCT ATG AC) and pHENseq (CTA TGC GGC CCC
ATT CA). Briefly, 1 pi (-250 ng/ml) of template was mixed with 3.2 pmol primer, 8 pi
Big Dye terminator ready reaction mixture (PE Biosystems) and ddH20 to a final
volume of 20 pi. The sequencing condition consisted of incubations at 96 °C for 30
seconds, 48 °C for 15 seconds, and 65 °C for 4 minutes for 25 cycles. After the cycle
sequencing reaction was complete, the samples were filtered over centricept columns
that had been hydrated with 0.8 ml ddHaO for an hour. After hydration, the columns
were allowed to drain completely by gravity and centrifuged at 730 x g for 2 minutes.
The columns were then placed in sample collection tubes. Extension reaction mixture
was added onto the gel material in the column and centrifiiged at 730 x g for 2 minutes.
The samples were collected and dried in a vacuum centrifuge for 15 minutes. Before
being applied to the sequencing gel, the samples were resuspended in 3 ml sequencing
gel loading buffer and incubated at 95 °C for 3 minutes.
Sequence Analysis
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Sequences obtained were analyzed through the use ofGeneDoc software
(Nicholas and Nicholas, 1997). Briefly, sequences the variable heavy and light chains
obtained from three rounds of subtractive panning selection were aligned to variable
heavy sequences, DP-47/V2-23-JH4b, and variable light chain sequences, DPK-
9/02/012-JkI from V-Base (a comprehensive directory of all human germline variable
region sequences compiled from over a thousand published sequences, www.mrc-
cpe.cam.ac.uk). Once aligned, regions containing nucleotide differences were
further analyzed by translating the DNA sequence to protein. Translation products were
compared to the V-germline sequences above and residue substitutions were noted.
Cell Spreading/Adhesion Assay
Ability of scFvlO preparations to affect cell spreading was examined
microscopically by counting the number of spread cells (defined as cells with decreased
refractivity and formation of projections around the cell periphery), and total cells in the
microscopic field. Briefly, 10'’ cells were incubated at room temperature with purified
scFvlO preparation at concentrations 0,1, 5, and 10 pg/ml for 10 minutes. After
incubating, the cells were plated in triplicate on 24-well tissue plates and grown for 72
hours.
Statistical Analysis
Results are expressed as mean ± SD of three observations. The data shown are




Subtractive Cellular Selection with scFv Phage
A large semi-synthetic human scFv-phage library was used to search for novel
tumor-associated antigens by counter-selecting with the nontumorigenic cell line RWPE-
1 and panning (selecting) with the tumorigenic prostate cell line RWPE-2. Precautions
were taken to maintain the integrity of membrane antigens during panning to facilitate
subsequent identification of antigen by expression cloning using isolated scFv fi-agments.
To achieve this, fixed cells were used for panning to preserve surface antigens.
Non- binding clones were subtracted fi-om the library via preabsorption with fixed
RWPE-1 cells. After subtraction, the phages that did not bind were selected on fixed
RWPE-2 cells. This process was repeated 2 additional times (Figure 2). Before and after
each subtraction/selection cycle, the phage titer wais calculated by infecting
logarithmically growing XL1-Blue E. coli cells and plating infected cells on L-agar plates
containing ampicillin. The number of phage eluted fi-om RWPE-2 cells recovered after
one, two, and three rounds ofpanning was 3 x 10^, 5 x 10^, and 1x10^ cfu, respectively.
Figure 2 schematizes the enrichment and screening of the semi-synthetic scFv library (by
mixing the Tomlinson I and J libraries 1:1). This ratio ofphage was chosen based on the
previously reported sensitivity of specific phage isolation (de Wildt et al. 2000;
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Griffith et al. 1993). Clones that preferentially bound to tumorigenic cells and not to
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Figure 2. Scheme for selection and screening of I/J phages on tumorigenic cell
surfaces. A semi-synthetic phage-scFv library containing equal quantities of
scFv clones was absorbed to normal prostate cells. Non-binding phage were
recovered and paimed against tumorigenic cells for 3 rounds. Individual phages
were obtained and assayed for binding to cultured cells.
Screening of scFv Clones bv Cell ELISA
ScFv clones from the third round of selection were screened by cell ELISA on
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RWPE-2 cells and RWPE-1 prostate cell lines. This assay consisted of testing scFv
binding to both fixed and unfixed cells to determine whether or not the antigens were
affected by fixation. In both assays, 0.5 % hydrogen peroxide was applied to the cells to
block endogenous peroxidase activity. Soluble scFv was prepared from individual scFv
clones and tested for reactivity with RWPE-1 and RWPE-2 cells using cell ELISA.
Briefly, 20 clones were picked from the round 3 titer plate, inoculated into L-broth
supplemented with lOOpg ampicillin/ml and grown overnight at 37 °C. Eight out of 20
clones grew successfully. The remaining clones were then induced with 1 mM IPTG and
grown overnight at 30 °C. ScFvs were liberated from XL-1 Blue cells by freeze/thaw
lysis. The bacterial lysates were incubated with ~10^ RWPE-1 or RWPE-2 cells for 1
hour at room temperature. Non-binding scFvs were washed away, and the bound scFvs
were detected with 9E10 MAb (recognizes the c-myc tag) and horseradish peroxidase-
conjugated goat-anti-mouse Ab. All assays were performed in triplicate. Of the 8 clones
screened, all bound preferentially to RWPE-2 cells with the exception of scFv 18
(Figures 3 and 4). It was observed that fixation of the cells caused a small decrease in the
binding of the scFvs to both cell lines (Figures 5 and 6). However, the signal produced by
RWPE-2-specific scFvs was much higher than the signals produced by the controls and
RWPE-1 cells. Apparent differential binding affinity to RWPE-2 over RWPE-1 cells
encouraged repetition of this experiment using different secondary antibodies (for




Figure 3. Screening of scFv clones with 9E10 + goat-anti-mouse-HRP on unfixed










Figure 4. Screening of scFv clones with 9E10 + goat-anti-mouse-HRP on
unfixed RWPE-1 and RWPE-2 cells without H2O2 treatment. Values represent
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Figure 5. Screening of scFv clones with 9E10 + goat-anti-mouse-HRP on
glutaraldehyde-fixed RWPE-1 and RWPE-2 cells without H2O2 treatment.



















































Figure 6. Screening of scFv clones with 9E10+goat-anti-mouse-HRP on
glutaraldehyde-fixed RWPE-1 and RWPE-2 cells with H2O2 treatment. Values
represent the mean + SD for triplicate samples.
scFv18
Once it was determined that the clones bound to antigens on RWPE-2 cells, the
presence of scFv expression was confirmed via restriction digestion and Western blot
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analysis. Briefly, DNA from scFv clones was digested with Sfil/Notl and analyzed on a 1
% agarose gel to verify the presence of variable heavy chain insert (Figure 7). A band
size of ~200 bp was observed, which is representative of the heavy chain insert. The
upper band (~5 kb) represents the vector pHENl. The production of functional scFvs
was also verified via Western blot analysis (Figure 8). Briefly, freeze/thaw lysates were
produced from individual clones induced with IPTG. After being subjected to SDS-
PAGE, the presence of scFv production was detected by blotting with 9E10 MAb (1:1000
dilution, recognizes the c-myc tag) and horseradish peroxidase-conjugated goat-anti¬
mouse antibody (1:1000 dilution, recognizes the 9E10 MAb), respectively. It was
observed that all clones expressed functional scFvs; however, they showed varying
migration on SDS-PAGE. The varying size in migration is due to the fact that some of
the clones expressed truncated scFvs. The average molecular weight for all clones was 30
kDa.
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Figure 7. Sfi I/Not I digestion of scFv clones (heavy chain insert). Numbers
represent clone. Lane 1, Benchtop 1 kb ladder, Promega. 1 % Agarose.
M 5 6 8 10 12 14 16 18
Figure 8. Detection of scFv production by Western blot analysis. SDS-PAGE ofnickel
column-purified periplasmic extracte with 9E10 MAb and goat-anti-mouse-HRP (1:1000
dilution). Kaleidoscope marker (not visible) is in lane 1, Sigma.
Sequence Analysis
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To obtain DNA sequences of scFv clones 5-18, XL-1 Blue cells carrying the inserts
were cultured at 37 °C in L-broth supplemented with 1 % glucose (to suppress protein
expression) and 100 mg ampicillin/ml. DNA was extracted via miniprep and sequenced
using ABI Prism DNA sequencing kit. After the sequences were obtained, they were
compared to V-germline sequences representative of the variable heavy and light chains
using GeneDoc software. When compared to V-germline sequences (V-BASE) DP-47
V2-23 (Tomlinson 1992), JH4b (Matilla 1995), and 012/02/DPK-9 (Pargent 1991; Cox
1994), nucleotide substitutions in CDR2, CDR3, CDRL2, and CDRL3 of the heavy and
light chains were found (Figure 9).
The nucleotides where substitutions occur correspond to the CDRH2, CDRH3,










































Figure 9. DNA sequence of scFv clones obtained from subtraction/selection. The
boxed region contains nucleotide substitutions. The * represents the V germline
sequence.
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Since nucleotide substitutions were observed, the translation products were
analyzed to determine whether the clones encoded different proteins (Table 2). The
translation products were obtained by first reversing the DNA sequence and translating
the protein product using GeneDoc software.
Table 2. Protein sequences of clones identified using subtraction/selection.
Clone CDRH2 CDRH3 CDRL2 CDRL3
V-germline SAISGSGGSTYYADSVKG -ADYFDY AASSLQS QQSYSTP-
sequence
scFv 5 SDIGRSG*KTRYADSVKG RORRFDY KASDLQS OONMOSPK
scFv 6 SLINP*GORTSYADSVKG GFPSFDY RASSLQS QQRLTHPN
scFv 8 S*IGRNG*KTKYADSVKG TKRRFDY HASHLQS QQSDPPPA
scFv 10 SSIGA*GSATRYADSVKG NRVRFDY LASHLQS OOGAGAPH
scFv 12 STITSKG*HTRYADSVKG RPQRFDY RASSLQS OOVAAGPR
scFv 14 SAI*PSGLKTFYADSVKG RTRKFDY RASRLQS OOGHAWPR
scFV 16 SRINRSGTRT*YADSVKG GNRTFDY AASGLQS OOLMRRPE
scFvlS SRISK*GSSTAYADSVKG SARRFDY RASNLQS QQQARLPP
Table 2. All clones were selected from libraries based on a human framework comprising
the heavy-chain germline genes V3-23/DP-47 and JH4b and the K-light-chain genes
012/02/DPK9 and JkI with side chain diversity (eitherNNK or DVT encoded)
incorporated at 18 different positions in the antigen binding site (underlined).
* Indicates a TAG stop codon that is read as glutamine in the XL-1 Blue suppressor
strain. Underlined regions represent gene segments that contain residue substitutions. All
clones isolated encode for different protein products. Differences among the clones showed
that 18 different residues were present.
Deduced amino acid sequences further indicate that the putative contact residues
60
are different for different clones. These differences consisted of 18 amino acid
substitutions in the CDRH2, CDRH3, CDRL2, and CDRL3 domains. Similarities were
found in clones scFv 6 and scFv 12 where the same CDRL2 was obtained. In addition,
all clones were found to exhibit at least one amber stop codon in the CDRH2 domain;
clone 8 possessed two.
The physiochemical properties of the clones showed that most of the substitutions
were mainly polar amino acids. For example, clones scFv 5, scFv 6, scFv 12, and scFv 14
all had polar amino acid substitutions in the CDRL2 domain, which coincide with the k-
light chain V-germline sequence012/02/DPK9 and JkI.
Effect of scFv 10 on Cell Attachment and Spreading
The ability of scFv 10 to block cell spreading on plastic was analyzed. Data from
cell spreading and adhesion assays suggest that RWPE-1 and RWPE-2 require different
mechanisms for attachment. Upon exposure to scFv 10, RWPE-1 cells were foiind to
have lost their usual phenotype, whereas RWPE-2 cells remained attached; however, the
cells became more dispersed. These results coincide with previous data obtained by
Webber (1997) where it was found that RWPE-2 cells are not only anchorage-
independent, but also invasive. It was also found that RWPE-1 cells express a 6 integrin
while other prostate cells lines DU-145 and PC-3 have unstable, heterogeneous and/or
difftise expression ofa 6 integrin. In a similar experiment, LNCaP lacked a 6 integrin
(Webber 1997).
Prior to performing cell adhesion and cell spreading assays, the morphology of
RWPE-1 (Figure 10) and RWPE-2 (Figure 11) cells was observed over a 2-week period
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to determine whether or not the phenotype of the cell lines was affected by cell
doubling. Both cell lines were maintained in K-SFM media supplemented with BPE and
EGF. It was observed that after two weeks of growth, RWPE-1 cells became more
cuboidal in appearance while RWPE-2 cells retained their phenotype (flattened). Both
results coincide with previous data obtained from Webber (1997). The reasoning behind
their differences in appearance was attributed to the differential expression ofcell surface
molecules that are necessary for normal cell ftmction. For example, Webber noted that
RWPE-1 cells expressed a-6 integrin uniformly, while other prostate cancer cell lines
either exhibit diffuse expression (found in small amounts or not contained in focal
adhesion points) or completely lack the molecule. It was also demonstrated that when
grown on Matrigel, which is 60 % laminin, RWPE-1 cells were found to have retained
their polarity, which is indicative of normal cell function. RWPE-2 cells, on the other
hand, were found to not be polar and grew in a dispersed fashion. It was concluded that
RWPE-2 cells lack cell surface molecules (i.e. a-6 integrin) that are needed for cell: cell
and cell: matrix adhesion (Webber 1997).
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Figure 10. Growth ofRWPE-1 cells under normal conditions after 1 week (A) and 2
weeks (B), (Magnification, 40 X)
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A
Figure 11. Growth of RWPE-2 cells under normal conditions after 1 week (A) and 2
weeks (B). (Magnification, 40 X)
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Therefore, previous data suggests that over time the number or type of cell
surface molecules expressed by RWPE-1 cells varies during cell differentiation. In
addition, cell attachment in RWPE-2 cells may rely on different adhesion molecules from
RWPE-1. To further analyze this hypothesis, both cell lines were analyzed for their
ability to adhere to culture plastic in the presence of scFv 10. In this assay, both cell lines
were grown in the presence of either buffer + media, Ipg/ml scFv 10, 5 ^g/ml scFv 10, or
10 pg/ml scFv 10 (Figure 12).
65
RWPE-1 RWPE-2
Figure 12. GrowlJi ofRWPE-1 and RWPE-2 cells preincubated with 0 pg/ml (A and E),
1 |xg/ml (B and F), 5 pg/nd (G and G), and 10 pg/ml (D and H), scFvlO. Time period
was 72 hours (Magnification, 100 X).
66
The ability of scFv 10 to affect cell attachment and spreading was examined. A
preparation containing scFv 10 was able to block spreading ofRWPE-1 (Figure 12 A-D)
cells on tissue culture plastic. However, scFv 10 did not block cell spreading ofRWPE-2
(Figure 12 E-H) until lOmg/ml scFv 10 was used. These results suggest that RWPE-2
may express more copies of the cell surface molecule for spreading than RWPE-1, since
cell adhesion is not affected until a high concentration of scFv 10 is used.
Finally, cell survival conditions that inhibit cell spreading was examined. RWPE-1
cells were foimd to be rounded and necrotic (trypan blue exclusion) 72 hours after plating
with scFv 10. Overall, it was observed that scFv 10 significantly blocked cell adhesion




Figure 13. Inhibition ofRWPE-1 cells spreading in the presence of scFv 10. Bar
value represents a percentage of spread cells. One cell count was taken in three
wells was used for every experimental condition. Values represent the mean + .SD
of the mean from 1 of 3 experiments.
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0 |ag/ml 1 |i,g/ml 5 fxg/ml 10 ng/ml
scFv 10
Figure 14. Inhibition ofRWPE-2 cells spreading in the presence of scFv 10.
Bar value is represents a percentage of spread cells. One cell count was taken
in three wells was used for every experimental condition. Values represent
the mean i^SD of the mean from 1 of 3 experiments.
Screening ofAdditional Clones from the First Selection
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An additional 41 clones were picked from the same round 3 titer plate used in the
previous assays and analyzed for binding activity to determine if other clones exhibited
preferential binding to RWPE-2 cells. It was found that none of the clones picked,
including the previous eight, exhibited preferential binding to RWPE-2 cells after 3







Figure 15. Screening of additional 41 clones and 8 original clones on fixed
RWPE-1 and RWPE-2 cells with protein L-HRP. The above graph represents
the average signal obtained from three independent experiments.
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Selection and Screening ofCells with the Tomlinson Protocol
Since it was found that the clones isolated in the initial investigation recognized
both RWPE-1 and RWPE-2, another selection and screening was carried out using a
modified version of the Tomlinson protocol on the same batch of cells in native form
(unfixed). In addition, protein L-HRP was used as a secondary antibody to reduce the
amount of background signal obtained during the screening process. Using cells in
suspension in immunotubes during selection instead of cells fixed to culture plates also
modified the protocol. The controls for these experiments were secondary only, GFP 17
plus secondary, cells plus secondary, scFv 10 plus secondary, and TGI lysate plus
secondary (Figure 18). In all three experiments, clone 44 bound preferentially to RWPE-
2 cells (Figures 16, 17, and 18). The remaining clones' signals could be due to their
binding nonspecifically to the cells. The titers of phage clones after three rounds of
selection were 4.6x 10*, 2.0 x lO’, and 4.0 x 10^ cfu, respectively. The results of these






Figure 16. Trial 1 screening of clones from the modified Tomlinson protocol
on high passage number, fixed RWPE-1 and RWPE-2 cells with protein L-





Figure 17. Trial 2 screening of clones from the modified Tomlinson protocol on
high passage number, fixed RWPE-1 and RWPE-2 cells with protein L-HRP. The

























Figure 18. Trial 3 screening of clones from the modified Tomlinson protocol on
high passage number, fixed RWPE-1 and RWPE-2 cells with protein L-HRP. The





Figure 19. Average signals of clones from the modified Tomlinson
protocol on fixed high passage number RWPE-1 and RWPE-2 cells with
protein L-HRP. The * represents clone 44.
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The results above demonstrate the effect of long-term culturing on cell
surface antigens, since the assays represent signals obtained with increasing passage
numbers. To analyze the possibility of these changes, the eight clones isolated from the
first selection were screened with protein L-HRP on unfixed low passage number (37
passages) and high passage number (100 + passages) cells (Figures 20 and 21,
respectively). The controls used in this experiment were buffer plus secondary,
secondary antibody only, XL-1 Blue lysate plus secondary, anti-GFP scFv (recognizes
green fluorescent protein) plus secondary, and cells + buffer (to check for signal variation
of the wells). It was found that the signals of the 6 clones previously selected clones
showed no significant difference between the two cell lines (Figure 20). However, the
signal produced by scFv 12 and scFv 16 was higher on long-term culture RWPE-2 cells








Figure 20. Screening of 8 original clones on low passage number RWPE-1 and
RWPE-2 cells with protein L-HRP. The above graph represents the average signal








Figure 21. Screening of original 8 clones on high passage number RWPE-1 and
RWPE-2 cells with protein L-HRP. The above graph represents the average signal
obtained from three independent experiments. Values represent the mean + SD for
triplicate samples.
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ELISA results showed that scFv 12 and scFv 16 bind preferentially to RWPE-2
cells in the high passage number (Figure 21) cultured cell assay, which suggests that
these clones bind to cell surface proteins that are present on high passage number cells.
However, the remaining clones produced varying signals in binding to both cell lines.
The variability in these clones could be due to their recognition of proteins that undergo
modifications while in culture.
Since high passage number culture cells (more than 100 passages) produced
varying results when compared to the results obtained from low passage number cells (37
passages), it was suspected that the cells had undergone phenotypic changes while in
culture. In addition, fixation ofcells was foimd to decrease the signal produced by the
clones (Figures 3,4, 5, and 6). Therefore, clones from the same library were selected on
newly obtained cells without fixation using the Tomlinson. The controls for these
experiments were secondary only, GFP 17 plus secondary, cells plus secondary, scFv 10
plus secondary, and TGI lysate plus secondary (Figure 24). The number ofphage clones
eluted from RWPE-2 cells after 3 rounds of selection were 2.24 x 10^, 27 x 10^, and 4.32
X 10^, respectively (Figures 22,23, and 24). Sixty clones were tested for specificity to
RWPE-2 cells via cell ELISA. The following graphs represent cells that had undergone
37 passages performed in triplicate (trial 1, trial 2, and trial 3). The results of these assays















Figure 22. Trial 1 screening of clones using the modified Tomlinson protocol
on low passage number RWPE-1 and RWPE-2 cells with protein L-HRP. The




Figure 23. Trial 2 screening of clones using the modified Tomlinson protocol
low passage number RWPE-1 and RWPE-2 cells with protein L-HRP. The *





Figure 24. Trial 3 screening of clones using the modified Tomlinson protocol on
low passage number RWPE-1 and RWPE-2 cells with protein L-HRP with




Figure 25. An average signal of clones using the modified Tomlinson protocol
on low passage number RWPE-1 and RWPE-2 cells with protein L-HRP with
controls. The * represents clones 26, 37, and 46.
These results demonstrate selection ofphage-displayed scFvs on fresh cells
produced clones that bind preferentially to the RWPE-2 cell line. However, some
variability was observed in the other clones. The variability seen in these experiments
could be due to the modification of cell surface proteins during selection or nonspecific
binding of clones. Since both RWPE-1 and RWPE-2 cells are both HPV immortalized
cell lines, the passage number that phage selection is performed is important. Recent
studies have found that the passage number of transformed cells in culture is critical
when performing assays on surface proteins (Heckman et al. 2004).
Overall, it was observed that 3 out of the 60 clones tested gave consistent results in
all three assays (clone 26, clone 37, and 46 marked as *).
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A comparison of the signals produced by scFv clones on both high peissage
number and low passage number RWPE-2 cells was performed. Analyses of these
signals show that the most reliable results were obtained from clone 46 (Figure 26). In
recent studies, researchers have screened anywhere from 8,000 clones to 20,000 clones.
In these investigations, usually 3 to 5 target-specific clones were identified (Norhona
1999; Holt 1998). In this study, 1 target-specific clone was selected out of 169 clones. In
light of these results, it has been determined that the best method for isolating cell surface
protein-specific clones is the use ofunfixed cells with low passage numbers.
I □ Clone 44 □Clone 26 □ Clone 37 0Clone 46
Figure 26. Binding of scFv Clones to Low Passage Number and High




The concept of specific tumor therapy is based on the assumption that tumor-
specific antigens actually exist, and this has been proven only for purified tumor Ags,
which are of limited use in tumor therapy and diagnosis (Kawakami et al. 1996). This
investigation has shown that antibodies defining antigens expressed on the surface of
tumorigenic cells can be selected from a naive antibody-phage library; however, the
nature of the antigen and the passage number of the cells used serve as critical factors.
These results coincide with results obtained by Hoogenboom et al. (1999), where the
nature of the antigen target was found to have a profoimd effect on the outcome of the
selection.
This study was designed for the isolation of semisynthetic human scFvs that react
selectively with cell-surface antigens on human PCa cells. The source of scFv genes
was a human semi-synthetic scFv library that contains 10* different clones. The first
selection procedure involved absorption of scFv-phage against whole, fixed RWPE-1
cells (normal prostate cells), followed by panning against whole, fixed RWPE-2 cells
(tumorigenic prostate cells derived from RWPE-1). After three panning cycles, the
signals produced by the clones were analyzed on both fixed and unfixed cells. Two
clones (scFv 12 and scFv 16) were found to bind preferentially to RWPE-2 cells;
however, it was determined that fixation of the cells reduces binding of the scFv clones
to their target antigen(s). A second selection was performed to determine the effect that
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the passage number had on scFv binding. The results from this assay produced one
RWPE-2-specific clone (46) on the low passage number cells. Overall, it was found that
cells that were in culture over an extended time exhibited phenotypic changes that caused
surface antigens to become altered, which was exhibited by a reduction in scFv signals
during cell ELISA. In addition, one clone, scFv 10, was found to bind to both cell lines,
but have different effects on cell adhesion and cell spreading.
The first step in developing a targeted cancer therapeutic is generating a ligand that
binds to a receptor which is either tumor-specific or sufficiently overexpressed in tumors
to provide targeting specifically. The use of a transfected cell line allows selection of
Abs to native receptors without the need for protein expression or purification (Aitner et
al. 2001). Also, the isolation of cell-surface-specific Abs prerequisites the functional
expression ofAg on intact cells, which are maintained routinely by cell culture.
However, long term culturing of tumor cells could alter their Ag expression patterns and
stable fixation ofwhole cells is not guaranteed on plastic surfaces during stringent
screening procedures (Tur 2003).
In a study by Heckman (2004), it was observed that during long-term culture,
certain epithelial cell lines become neoplastic while accumulating changes in cell shape.
This phenomenon could account for the variation in the cell ELISA assays performed in
this investigation. In Heckman's study, it was found that protrusions form at the edge of
p21-activated cells. These protmsions could possibly prevent the binding of scFvs to
antigens present within these protmsions. Hence, cell lines that have been cultured for
more than 10 passages should not be used in cell surface protein assays (Heckman 2004).
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Selection of phage Ab on whole cells is affected by many different parameters,
including the quality of the Ab library, the manner of display (p3 or p8 fusion in phage or
phagemid), the Ag cell-surface density, and Ag concentration. The Ag of interest should
also stay intact and the cells should not lyse during the selection and washing procedure.
Hence, the number of studies addressing the derivation ofphage Abs to cell-surface Ags
by cell panning procedures is very limited (Hoogenboom et aJ. 1999). It was speculated
that whole tumor cells which express tumor antigens might be considered as a means for
replacing purified tumor antigens; however, it was reported that panning and screening
by phage display was non-specific (Ridgway 1999). This could be attributed to a much
lower antigen density and many complicated antigens (Nie et al. 2002).
In all types ofpanning, phage has the tendency to bind nonspecifically, especially
in early rounds of selection (Barbas et al. 2001). Panning with intact cell surfaces
presents an additional challenge, because cell surfaces contain many nonspecific antigens
in the form ofproteins, carbohydrates, and lipids (Siegel and Silberstein 1994; Siegel
1995). Negative selection strategies can be used in which the phage libraries are
incubated with cells that lack the target antigen; however, each negative selection cycle
removes only a small percentage of nonspecific phage. In addition, negative selections
can also remove some specific phage, and multiple cycles of negative selection can
deplete a library containing only low levels of the desired phage. These problems might
explain why many cell-surface panningmethods have not produced as wide a diversity of
positive clones as methods that use purified antigens (Barbas et al. 2001).
Counter-selection is useful when the Ag is present at much higher levels on target
than control cells. Antigens that are present in tumors but absent from normal tissues
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have been much sought after, but have, thus far proved elusive (Ridgway 1999).
Recently, several studies have identified recombinant antibodies that recognize
predefined targets. For example, Belizaire (2003) was able to isolate a murine ICAM-1-
specific peptide by panning a library directed against ICAM-1 on COS 7 cells transfected
with ICAM-1. In his study, subtractions with cells not expressing ICAM-1 were used for
preabsorption. Volkel (2004) also used cells that expressed the target at higher levels
than control cells in their study to isolate endothelial cell-specific scFvs. In addition,
Schwarz (2004) was able to isolate scFv clones that bound selectively to activated
platelet integrin alpha IIbbeta3 cells and not non-activated cells.
Selection of target-specific clones can also be facilitated with the use of immunized
libraries. Studies that involved this approach includes anti-MUC-1 scFvs isolated by
Winthrop et al. (2003) and anti-NCA-2 scFvs isolated by Paus et al. (2003). In both of
these studies, libraries were constructed from mRNA from mice immunizedwith purified
antigen.
Recently, Pimenidou et al. (2004) have been able to isolate anti-CD43 scFvs by
first panning with synthetic CD43 and native CD43 followed by selection on synthetic
CD43 peptide with a naive library. Hence, the effectiveness of isolation of recombinant
antibodies is also dependent on the specificity of the clones. Although subtractive
selection has been a successful route for isolating cell line-specific clones (Cai et al.
1995), there are disadvantages to this method. For example, a potential disadvantage of
using cell lines for library clearing is that immortal cells can be expected to regulate the
expression of antigens associated with proliferation that could also be tumor markers and
thereby result in the loss of tumor-reactive scFv clones during selection (Kupsch 1999).
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One way to circumvent this problem would be the use of newly isolated cells (primary
cultures) that have not been immortalized. Not only does this alleviate the problem of
inducing the expression of proliferation markers, but it also provides a mechanism for
subtracting clones on cells that do not express tumor-like qualities.
Hybridoma technology has been used with tremendous success for the
identification of novel cell surface Ags by mouse MAbs. However, the production of
antibodies by hybridomas for therapeutic applications has consistently given poor results
(Winter and Milstein 1991). Therefore, the approach employed in this investigation
should be applicable to the isolation ofhuman antibodies against tumor markers or novel
cell surface markers in general.
Begent et al. (1994) showed that an anti-CEA scFv when injected into patients
binds tumor cells, with high specificity in patients. ScFvs against tumorigenic cells are
therefore of diagnostic value for the detection ofmetastatic disease by radioimaging of
patients (Kang et al. 1997). Whole human tumor-specific antibodies or scFv fusions to
effector molecules such as toxins could be engineered for use in passive antibody-
mediated immunotherapy (Kupsch et al. 1999).
Another application would be the use of recombinant antibodies in targeted drug or
gene delivery (Martin et al. 1998). Several groups have successfully selected antibody
phage libraries on whole cells. One group used pairs of untransfected and transfected
COS cells for library preclearing/selection (Portolano et al. 1993). Similarly,
combinations of erythrocytes ofdifferent blood groups have been used to select blood
group-specific antibody phage (Marks et al. 1993). However, both of these investigations
involved either a target cell line that expressed high levels ofAg or clearly defined
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targets. A difficulty of the use of large, non-immune or synthetic repertoires for selection
on complex antigens is that they contain antibodies to a whole range of epitopes
expressed on the antigenic surface (Marks et al. 1991; Nissim et al. 1994). Therefore,
antibodies with the desired specificity may be largely obscured by clones binding to
irrelevant epitopes (Mutuberria et al. 1999). To direct the selection of phage antibodies
towards specific epitopes, subtraction and depletion strategies have been devised and
successfully used (Ames et al. 1994; Cai and Garen 1995; de Kruifet al. 1995;
Kipriyanov et al. 1996; Parsons et al. 1996; Strausbol-Gron et al. 1996; Palmer et al.
1997; Xu et al. 2004; Schwarz et al. 2004; Popkov et al. 2004). In addition, the removal
of non-relevant clones can also be achieved by alternating selection on different antigen
sources to home in on antigen-binding clones (Shukla 2005).
Recently, it was reported that some of the impediments for isolating tumor specific
Abs could be alleviated through the used ofmodified fixation procedures (Nie et al.
2002) or the use ofmembrane fractions (Tur et al. 2003). In the latter investigation, the
use ofmembrane fractions was shown to be generally applicable to identify novel cell-
surface antigens and their corresponding Abs.
Antigen phage panning method offers a potential direct and broadly applicable
route to the identification of human antibodies suitable for antitumor therapy. This
strategy favors the identification of antibodies to highly expressed antigens because high
antigen levels are anticipated to facilitate enrichment of cognate-scFv-phage during
panning. This seems desirable because high-level antigen expression may also facilitate
tumor localization of antitumor antibodies in vivo. Hence, a reliable model for selection
tumor antigen-specific scFvs is highly desirable.
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Nonimmune phage antibody libraries are currently being used as a source of
diagnostic and therapeutic antibodies. In addition, new genes are rapidly being identified
by the genome projects, and the next generation of experiments will shift to elucidating
the function of the protein products encoded by these newly identified genes (Lander
1996). The production of antibodies with phage-displayed libraries is suited for the
large-scale determination of protein function. For example, once a gene has been
sequenced, the protein(s) that it encodes can be overexpressed and then used to rapidly
select phage-displayed antibodies. The resulting antibodies would provide
immunological reagent for protein characterization. In addition, the production of
antibodies with phage display also provides access to the genes that encode specific
antibodies. These antibody genes can be used to express antibody proteins within cells to
block and elucidate the function of specific molecules in vivo (Marasco 1997; Biocca et
al. 1994; Marasco 1997).
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